

Progenetix & Beacon+

A cancer genomics reference resource powered by GA4GH standards

Michael Baudis | Roche Data Science Seminar | 2022-06-27

1992



Heidelberg

Student of medicine | doctoral thesis in molecular cytogenetics @ DKFZ (Peter Licher) | resident in clinical hematology/oncology | data, clinical studies & cancer systematics

2001



Stanford

Post-doc in hemato-pathology (Michael Cleary) | molecular mechanisms of leukemogenesis | transgenic models | expression arrays | systematic cancer genome data collection | *Progenetix* website

2003



Gainesville

Assistant professor in paediatric haematology | molecular mechanisms of leukemogenesis | focus on bioinformatics for cancer genome data analysis

2006



Aachen

Research group leader in genetics | genomic array analysis for germline alterations | descriptive analysis of copy number aberration patterns in cancer entities

2007




Zürich

Professor of bioinformatics @ DMLS (2015) | systematic assembly of oncogenomic data | databases and software tools | patterns in cancer genomes | *Progenetix* & *arrayMap* resources | GA4GH | SPHN | ELIXIR




Genome screening at the core of “Personalised Health”



- ▶ **Genome analyses** (including transcriptome, metagenomics) are core technologies for Personalised Health™ applications
- ▶ The unexpectedly large amount of **sequence variants** in human genomes - germline and somatic/cancer - requires huge analysis efforts and creation of **reference repositories**
- ▶ **Standardized data formats** and **exchange protocols** are needed to connect these resources throughout the world, for reciprocal, international **data sharing** and **biocuration** efforts
- ▶ Our work @ UZH:
 - ▶ **cancer genome repositories**
 - ▶ **biocuration**
 - ▶ **protocols & formats**



BETTER, CHEAPER, FASTER
The cost of DNA sequencing has dropped dramatically over the past decade, enabling many more applications.



The future of DNA sequencing. Eric D. Green, Edward M. Rubin & Maynard V. Olson. Nature; 11 October 2017 (News & Views)





Geographic distribution of 104'543 genomic array, 36'766 chromosomal CGH and 15'409 whole genome/exome based cancer genome datasets


Types of genomic alterations in Cancer

Imbalanced Chromosomal Changes: CNV


- Point mutations (insertions, deletions, substitutions)
- Chromosomal rearrangements
- Structural chromosomal Aberrations
- **Regional Copy Number Alterations**
(losses, gains)
- Epigenetic changes (e.g. DNA methylation abnormalities)




Somatic Copy Number Variations



Gain of chromosome arm 13q in colorectal carcinoma



2-event, homozygous deletion in a Glioblastoma




MYCN amplification in neuroblastoma
(GSM314026, SJNB8_N cell line)

low level/high level copy number alterations (CNAs)


arrayMap



Quantifying Somatic Mutations In Cancer



Pan-Cancer Analysis of Whole Genomes (PCAWG) data show widespread mutations in non-coding regions of cancer genomes (Khurana et al., Nat. Rev. Genet. (2016))




On average ~19% of a cancer genome are in an imbalanced state (more/less than 2 alleles); Original data based on 43654 cancer genomes from progenetix.org

Somatic Mutations In Cancer: Patterns

Making the case for genomic classifications


Some related cancer entities show similar copy number profiles




Somatic CNVs In Cancer

Recurrent mutation patterns

How can those patterns be used for classification and determination of biological mechanisms?



A genomic copy number histogram for malignant medulloblastomas, the most frequent type of pediatric brain tumors, displaying regions of genomic duplications and deletions. These can be decomposed into individual tumor profiles which segregate into several clusters of related mutation patterns with functional relevance and clinical correlation.



Progenetix Genomics Resource


From Genomic Experiments to Experimenting with the Beacon API




Comparative Genomic Hybridization

Molecular-Cytogenetic Technology for Genomic Imbalance Screening

- Molecular-cytogenetic technique to identify regional genomic copy number variations (CNV/CNA)
- based on ***in situ*** suppression **hybridization** of labeled **genomic** tumor and reference DNA against a karyotypically normal metaphase chromosomes
- analysis of relative fluorescence ratio allows **semi-quantitative copy number** read-out
- **indirect** attribution of involved target genes through cytogenetic bands (megabase resolution)




CGH-Experiment: **a** Hybridisierung mit Tumor-DNA; **b** Hybridisierung mit normaler menschlicher DNA als Kontrolle; **c** Überlagerung der Signale; **d** Bänderungsfärbung zur Identifizierung der Chromosomen



Auswertung: Summationsprofil der computergestützten Analyse mehrerer Metaphasen des dargestellten Falles; die Profilausschläge stehen für Zugewinne bzw. Verluste von chromosomalen Anteilen im Tumorgenom


- Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258:818-821.
- Joos S, Scherthan H, Speicher MR, Schlegel J, Cremer T, Lichter P. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet. 1993;90:584-589.

Let's build a database!





| Tuesday February 27, 1996

... using archaic tools



| Tuesday September 08, 1992




Collection and Transformation of Chromosomal Imbalances in Human Neoplasias for Data Mining Procedures

michael baudis, dept. of pathology, stanford university

Although the deciphering of the human genome has been pushed forward over the last years, little effort has been made to collect and integrate the treasure trove of clinical tumor cases analyzed by molecular-cytogenetic methods into current data schemes. Publicly announced at BCATS 2001, since then [progenetix.net] has been established as the largest public source of chromosomal imbalance data with band-specific resolution. Targets for the use of the data collection may be the description of prediction of oncogene and suppressor gene loci, identification of related loci for pathway creation, and especially the combination of the data with expression array experiments for filtering of relevant genes among the deregulated candidates.


Chromosomal imbalances in 5478 clinical cases from 196 publications
Although not as prominent as in specific subgroups, this large collection shows the non-random distribution of chromosomal gains (green) and losses (red).



Material and Methods Chromosomal aberration data of more than 5478 cases from 196 publications describing results of Comparative Genomic Hybridization (CGH) experiments were collected. Minimal requirements were diagnosis of a malignant or benign neoplasia, analysis of clinical tumor samples and report of the analysis results on a case by case basis, resolved to the level of single chromosomal bands. Data was transformed from the diverse annotation formats to standardized ISCN "rev ish" nomenclature. For the transformation of the non-linear ISCN data to a two-dimensional matrix with code for the aberration status of each chromosomal band per case, a reverse pattern matching algorithm was developed in Perl. Graphical representations and cluster images are generated for all different subsets (Publications, ICD-O-3 entities, meta-groups) and presented on the progenetix.net website.




Clustering of the band averages for the different ICD-O entities
Two dimensional clustering groups related disease entities and chromosomal bands with related aberrations.



Results Out of 4896 tumor samples, 3862 (79%) showed chromosomal imbalances by CGH. The average per band probability was 4.5% for a loss (max. 12.9% at 13q21) and 6.5% for a gain (max. 15.6% at 8q23). Differences between neoplastic entities showed in the average frequency and distribution pattern of imbalanced chromosomal regions. Tumor subsets (10 or more cases) with the strongest hot spots for losses were small cell lung carcinomas (ave. 23.3% with max. 96.2% at 3p14p26) and pheochromocytomas (ave. 10.9% with max. 92.7% at 3p); prominent gain maxima were found in pure high grade infiltrating duct carcinomas of the breast (ave. 5.9% with max. 95.7% at 11q13), T-PLL (ave. 4.7% with max. 81.8% for whole 8q) and dedifferentiated liposarcomas (ave. 10.4% with max. 81.8% at 12q13), among others. By cluster analysis, different combinations of chromosomal hot spot regions could be shown to occur in tumors subsummed in the same diagnostic entity; the example of neuroblastomas is shown.

Examples of hotspots of genomic imbalance
SCLC, pheochromocytoma, high grade DCIS, T-PLL, dedifferentiated liposarcoma



Conclusion So far, progenetix.net project was able to:
1. collect a large dataset of genomic aberration data generated through a molecular-cytogenetic screening technique (CGH)
2. develop the software tools to transform those data to a meta format compatible to commonly used genomic interval descriptions
3. produce graphical and numerical output from those data for hot spot detection and statistical analysis.

For future approaches, the data collection will be valuable for filtering data from expression array experiments for relevant genes, and possibly for the description of common and divergent genetic pathways in the oncogenetic process of different tumor entities. The transformed raw data of the progenetix.net collection is available for research purposes over the website.

Distinction of histologically related through their chromosomal aberration pattern
Amplification of the REL locus on 2p16 and gain of 9p(ter) distinguishes primary mediastinal B-cell lymphomas (PMBL, right) from diffuse large cell lymphomas (DLCL, left). The distinction may have clinical implications



Identification of different aberration patterns in Neuroblastoma (289 cases)
N-Myc (2p25) amplification is the hallmark of a subgroup, showing only consistent loss of the terminal portion 1p. Other groups are defined by the loss of parts of 11q, or a "chromosomal instability" phenotype. Gains on 17q are a common feature of all groups. Those patterns may be combined with gene-level information to reconstruct the different pathways leading to malignant transformation.

Progenetix Database in 2003

Text conversion for CNVs

- articles and supplements with **cytoband-based rev ish CGH** results
- sometimes rich, but **unstructured** associated information
- PDFs** readable, but **not well suited for data extraction** (character entities, text flow)

progenetix

TABLE 3. Comparison of Primary Tumors and Metastases by CGH

Case	Gain in common	Loss in common	Primary tumor only	Metastasis only
108		18		
113	7, 8q24-qter, 13q11-qter, 20q11-qter, Xq11-Xter	1p33-pter, 2p21-pter, 4q24-qter, 15q11-q15, 17p11-pter, 18		
LM	12q22-qter, 15q23-qter, 17q11-ter, 20p11-p12, 20q11-ter, 22q11-ter	1p11-p32, 1q24-31, 4, 13q11-pter, 17p11-pter, 18, 20p11-ter	11p11-pter-	12+
145	4q26-q28, 6p11-p13, 8p11-p12, 920q11-qter	1p11-pter, 4q31-qter, 6q11-qter, 8p12-pter, 11, 15q11-qter, 16q11-qter, 17p11-pter, 18, 21q11-qter	13q21-qter+, 20p11-pter-	8q11-qter+, 10-, 6p21-pter-
53	7, 8q11-qter, 9q33-qter, 13q11-qter, 20p11-p12, 20q11-qter	4p13-pter, 4q21-qter, 8p12-pter, 15q14-qter, 18q11-qter, 20p12-pter	5p11-pter-, 5q13-qter-, 14q11-qter-	11+, 16p11-pter+, 17q11-qter+, 19+, 21q11-qter+, 22q11-qter+
147	7, 13q11-qter, 20q11-qter	8p21-pter, 18	4p14-pter-, 4q28-qter+, 8p11-21-, 17q11-q2+, 21q11-qter-	11q22-qter+, 16+, 1p11-33-

TABLE 1. Clinical Data

Case number	Age	Sex	Site	Stage ^a	Grade ^b	Diagnosis of metastatic disease ^c
2	40	M	Transverse colon	IV	3	Synchronous
6	79	M	Ascending colon	IV	2	Synchronous
9	73	M	Transverse colon	II	2	N/A
11	56	M	Rectosigmoid	IV	2	Metachronous
12	70	F	Sigmoid colon	IV	2	Synchronous
13	65	M	Descending colon	II	9	Synchronous
14	60	M	Rectum	III	3	Metachronous
15	51	F	Rectum	III	2	Metachronous
19	63	M	Rectosigmoid Junction	III	2	Synchronous
20	63	M	Rectum	IV	9	Metachronous
21	64	F	Sigmoid colon	IV	2	Synchronous
35	71	M	Rectum	III	9	Metachronous
49	72	M	Cecum	IV	3	Synchronous
53	72	F	Sigmoid colon	IV	2	Synchronous
104	61	M	Sigmoid colon	IV	2	Metachronous
105	58	M	Ascending colon	II	2	Metachronous
107	77	F	Cecum	IV	2	Metachronous
108	53	F	Splenic flexure	IV	2	Synchronous
112	68	M	Rectum	III	3	Synchronous
113	41	M	Splenic flexure	IV	2	Synchronous
114	49	M	Splenic flexure	IV	3	Synchronous
116	73	M	Rectosigmoid	III	9	Metachronous
120	24	F	Descending colon	IV	2	Synchronous
123	62	F	Rectum	III	2	Metachronous
124	42	M	Rectum	IV	9	Synchronous
145	70	M	Rectosigmoid	IV	2	Synchronous
147	86	F	Cecum	IV	2	Synchronous

^aAJCC/UICC staging system (Hutter and Sabin, 1986).^bGrade of primary tumor: 1–3, low, moderate, high grade; 9, grading unknown.^cSynchronous, diagnosis of metastatic disease within 12 months following diagnosis of primary tumor; metachronous, diagnosis of metastatic disease after 12 months or later.


GENES, CHROMOSOMES & CANCER 25:82–90 (1999)

Chromosome Arm 20q Gains and Other Genomic Alterations in Colorectal Cancer Metastatic to Liver, as Analyzed by Comparative Genomic Hybridization and Fluorescence In Situ Hybridization

W. Michael Korn,¹ Toru Yasutake,² Wen-Lin Kuo,¹ Robert S. Warren,³ Colin Collins,¹ Masao Tomita,² Joe Gray,¹ and Frederic M. Waidman¹

Data "Pipelines"

DATA PIPELINE



DATA PIPELINE

BIOCURATION BIOINFORMATICS



NCBI GEO Accession Display

Series GSE640034 Public on Sep 07, 2013

Organism: Human

Experiment type: Genomic variation profiling by array

Summary: This study investigates genomic variation in chronic lymphocytic leukemia (CLL) specimens with prognostic significance.

Overall design: Overall design experiment, Test vs. Specimens vs. Reference human genome

Contributor(s): Houldsworth J, Venkata T, Guttagji A, Thoduri V, Yan XI et al.


Phone: +41 61 267 32 32

Address: University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland

Sample ID: GSE640034

Platform: Agilent G1317P Lymphoma (Agilent Probe ID)

Supplementary file: GSE64034.RAW.tar



arrayMap

985 experimental series

333 array platforms

253 ICD-O cancer entities


716 publications (PubMed entries)

For the majority of the samples, probe level visualization as well as customized data representation facilitate gene level and genome wide data review. Results from multi-case selections can be connected to downstream data analysis and visualization tools, as we provide through our Progenetix project.

arrayMap is developed by the group "Theoretical Cytogenetics and Oncogenomics" at the Institute of Molecular Life Sciences of the University of Zurich.

Platforms (1): GPR100, Agilent G1317P Lymphoma (Agilent Probe ID)

Supplementary file: GSE64034.RAW.tar



informa healthcare

ORIGINAL ARTICLE RESEARCH

Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia

Jane Houldsworth¹, Asha Guttapalli¹, Venkata Thoduri¹, Xiao Jie Yan¹, Geeta Mendiratta¹, Tamja Zelenka², Gouri Nangappa², Wei Chen², Supratik Pati², Anthony Mato², Jennifer R. Brown², Kanti Rai², Department of Epidemiology and Biostatistics¹ and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY, USA; Department of Medicine, Division of Hematology/Oncology, Department of Medicine, Division of Hematology/Oncology, David Hahn Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA, USA


Abstract

Genomic imbalance (GCI) has been fully leveraged in a prognostic setting in chronic lymphocytic leukemia (CLL). We used array-based genomic hybridization to identify 20 aberrations in CLL specimens. Based on these 20 aberrations, we defined a group with poor outcome (20R) exhibiting a gain of 11q13 and loss of 17q12, and a group with intermediate outcome (10I), with either a gain of 11q13 or loss of 17q12. The first treatment and overall survival (OS) of 20R was significantly lower than that of 10I. Gain of 11q13 and loss of 17q12 were determined to be independent prognostic factors. Gain of 11q13 and loss of 17q12 were associated with the presence of TP53 and ATM (11q13) and TP53BP1 (17q12) mutations. TP53 mutations correlated with the presence of ATM mutations. ATM mutations were associated with the presence of TP53BP1 mutations. These data support genomic imbalance evaluation in CLL by means of next-generation sequencing (NGS) and, more recently, massively parallel sequencing techniques. These methods are able to identify the location of GCI genes, identifying genes, and other mechanisms of GCI. TP53BP1 and ATM (11q13) and TP53 and ATM (17q12) that potentially have cytobiological significance. These genes, which are frequently integrated into diagnostic laboratories, are promising candidates for biomarkers. In addition, we identified recurrent copy number alterations (CNAs) at relatively low frequency that when considered poor risk aberrations. These findings may have clinical relevance when considering age and comorbidity.

Keywords: chronic lymphocytic leukemia, molecular genetics, prognostication

Introduction

The clinical course of patients with B-cell chronic lymphocytic leukemia (CLL) is highly variable, undergoing disease progression, with therapy, and eventually disease relapse. The clinical course of CLL is characterized by a long disease duration, with therapeutic intervention often required only after progression of the disease.



arrayMap

progenetix

ArrayExpress

E-MTAB-998 Comparative genomic hybridization array of human peripheral T-cell lymphoma clinical samples to study their genomic aberration profiles

Organism: Homo sapiens

Sample: E-MTAB-998 Click for detailed sample information and links to data

Description: Genomic aberration profiles of Peripheral T-cell Lymphoma, not otherwise specified (clinical samples)

Experiment type: comparative genomic hybridization array, in vitro comparative genomic hybridization, disease state

Context: IT: human tumor, lymphoid/haemopoietic tissue

Platform: Agilent G1317P Human Oligo Microarray

Investigation description: By array, Agilent Human Oligo Microarray

Sample and data relationship: E-MTAB-998-001, E-MTAB-998-002, E-MTAB-998-003, E-MTAB-998-004, E-MTAB-998-005, E-MTAB-998-006, E-MTAB-998-007, E-MTAB-998-008, E-MTAB-998-009, E-MTAB-998-010, E-MTAB-998-011, E-MTAB-998-012, E-MTAB-998-013, E-MTAB-998-014, E-MTAB-998-015, E-MTAB-998-016, E-MTAB-998-017, E-MTAB-998-018, E-MTAB-998-019, E-MTAB-998-020, E-MTAB-998-021, E-MTAB-998-022, E-MTAB-998-023, E-MTAB-998-024, E-MTAB-998-025, E-MTAB-998-026, E-MTAB-998-027, E-MTAB-998-028, E-MTAB-998-029, E-MTAB-998-030, E-MTAB-998-031, E-MTAB-998-032, E-MTAB-998-033, E-MTAB-998-034, E-MTAB-998-035, E-MTAB-998-036, E-MTAB-998-037, E-MTAB-998-038, E-MTAB-998-039, E-MTAB-998-040, E-MTAB-998-041, E-MTAB-998-042, E-MTAB-998-043, E-MTAB-998-044, E-MTAB-998-045, E-MTAB-998-046, E-MTAB-998-047, E-MTAB-998-048, E-MTAB-998-049, E-MTAB-998-050, E-MTAB-998-051, E-MTAB-998-052, E-MTAB-998-053, E-MTAB-998-054, E-MTAB-998-055, E-MTAB-998-056, E-MTAB-998-057, E-MTAB-998-058, E-MTAB-998-059, E-MTAB-998-060, E-MTAB-998-061, E-MTAB-998-062, E-MTAB-998-063, E-MTAB-998-064, E-MTAB-998-065, E-MTAB-998-066, E-MTAB-998-067, E-MTAB-998-068, E-MTAB-998-069, E-MTAB-998-070, E-MTAB-998-071, E-MTAB-998-072, E-MTAB-998-073, E-MTAB-998-074, E-MTAB-998-075, E-MTAB-998-076, E-MTAB-998-077, E-MTAB-998-078, E-MTAB-998-079, E-MTAB-998-080, E-MTAB-998-081, E-MTAB-998-082, E-MTAB-998-083, E-MTAB-998-084, E-MTAB-998-085, E-MTAB-998-086, E-MTAB-998-087, E-MTAB-998-088, E-MTAB-998-089, E-MTAB-998-090, E-MTAB-998-091, E-MTAB-998-092, E-MTAB-998-093, E-MTAB-998-094, E-MTAB-998-095, E-MTAB-998-096, E-MTAB-998-097, E-MTAB-998-098, E-MTAB-998-099, E-MTAB-998-100, E-MTAB-998-101, E-MTAB-998-102, E-MTAB-998-103, E-MTAB-998-104, E-MTAB-998-105, E-MTAB-998-106, E-MTAB-998-107, E-MTAB-998-108, E-MTAB-998-109, E-MTAB-998-110, E-MTAB-998-111, E-MTAB-998-112, E-MTAB-998-113, E-MTAB-998-114, E-MTAB-998-115, E-MTAB-998-116, E-MTAB-998-117, E-MTAB-998-118, E-MTAB-998-119, E-MTAB-998-120, E-MTAB-998-121, E-MTAB-998-122, E-MTAB-998-123, E-MTAB-998-124, E-MTAB-998-125, E-MTAB-998-126, E-MTAB-998-127, E-MTAB-998-128, E-MTAB-998-129, E-MTAB-998-130, E-MTAB-998-131, E-MTAB-998-132, E-MTAB-998-133, E-MTAB-998-134, E-MTAB-998-135, E-MTAB-998-136, E-MTAB-998-137, E-MTAB-998-138, E-MTAB-998-139, E-MTAB-998-140, E-MTAB-998-141, E-MTAB-998-142, E-MTAB-998-143, E-MTAB-998-144, E-MTAB-998-145, E-MTAB-998-146, E-MTAB-998-147, E-MTAB-998-148, E-MTAB-998-149, E-MTAB-998-150, E-MTAB-998-151, E-MTAB-998-152, E-MTAB-998-153, E-MTAB-998-154, E-MTAB-998-155, E-MTAB-998-156, E-MTAB-998-157, E-MTAB-998-158, E-MTAB-998-159, E-MTAB-998-160, E-MTAB-998-161, E-MTAB-998-162, E-MTAB-998-163, E-MTAB-998-164, E-MTAB-998-165, E-MTAB-998-166, E-MTAB-998-167, E-MTAB-998-168, E-MTAB-998-169, E-MTAB-998-170, E-MTAB-998-171, E-MTAB-998-172, E-MTAB-998-173, E-MTAB-998-174, E-MTAB-998-175, E-MTAB-998-176, E-MTAB-998-177, E-MTAB-998-178, E-MTAB-998-179, E-MTAB-998-180, E-MTAB-998-181, E-MTAB-998-182, E-MTAB-998-183, E-MTAB-998-184, E-MTAB-998-185, E-MTAB-998-186, E-MTAB-998-187, E-MTAB-998-188, E-MTAB-998-189, E-MTAB-998-190, E-MTAB-998-191, E-MTAB-998-192, E-MTAB-998-193, E-MTAB-998-194, E-MTAB-998-195, E-MTAB-998-196, E-MTAB-998-197, E-MTAB-998-198, E-MTAB-998-199, E-MTAB-998-200, E-MTAB-998-201, E-MTAB-998-202, E-MTAB-998-203, E-MTAB-998-204, E-MTAB-998-205, E-MTAB-998-206, E-MTAB-998-207, E-MTAB-998-208, E-MTAB-998-209, E-MTAB-998-210, E-MTAB-998-211, E-MTAB-998-212, E-MTAB-998-213, E-MTAB-998-214, E-MTAB-998-215, E-MTAB-998-216, E-MTAB-998-217, E-MTAB-998-218, E-MTAB-998-219, E-MTAB-998-220, E-MTAB-998-221, E-MTAB-998-222, E-MTAB-998-223, E-MTAB-998-224, E-MTAB-998-225, E-MTAB-998-226, E-MTAB-998-227, E-MTAB-998-228, E-MTAB-998-229, E-MTAB-998-230, E-MTAB-998-231, E-MTAB-998-232, E-MTAB-998-233, E-MTAB-998-234, E-MTAB-998-235, E-MTAB-998-236, E-MTAB-998-237, E-MTAB-998-238, E-MTAB-998-239, E-MTAB-998-240, E-MTAB-998-241, E-MTAB-998-242, E-MTAB-998-243, E-MTAB-998-244, E-MTAB-998-245, E-MTAB-998-246, E-MTAB-998-247, E-MTAB-998-248, E-MTAB-998-249, E-MTAB-998-250, E-MTAB-998-251, E-MTAB-998-252, E-MTAB-998-253, E-MTAB-998-254, E-MTAB-998-255, E-MTAB-998-256, E-MTAB-998-257, E-MTAB-998-258, E-MTAB-998-259, E-MTAB-998-260, E-MTAB-998-261, E-MTAB-998-262, E-MTAB-998-263, E-MTAB-998-264, E-MTAB-998-265, E-MTAB-998-266, E-MTAB-998-267, E-MTAB-998-268, E-MTAB-998-269, E-MTAB-998-270, E-MTAB-998-271, E-MTAB-998-272, E-MTAB-998-273, E-MTAB-998-274, E-MTAB-998-275, E-MTAB-998-276, E-MTAB-998-277, E-MTAB-998-278, E-MTAB-998-279, E-MTAB-998-280, E-MTAB-998-281, E-MTAB-998-282, E-MTAB-998-283, E-MTAB-998-284, E-MTAB-998-285, E-MTAB-998-286, E-MTAB-998-287, E-MTAB-998-288, E-MTAB-998-289, E-MTAB-998-290, E-MTAB-998-291, E-MTAB-998-292, E-MTAB-998-293, E-MTAB-998-294, E-MTAB-998-295, E-MTAB-998-296, E-MTAB-998-297, E-MTAB-998-298, E-MTAB-998-299, E-MTAB-998-300, E-MTAB-998-301, E-MTAB-998-302, E-MTAB-998-303, E-MTAB-998-304, E-MTAB-998-305, E-MTAB-998-306, E-MTAB-998-307, E-MTAB-998-308, E-MTAB-998-309, E-MTAB-998-310, E-MTAB-998-311, E-MTAB-998-312, E-MTAB-998-313, E-MTAB-998-314, E-MTAB-998-315, E-MTAB-998-316, E-MTAB-998-317, E-MTAB-998-318, E-MTAB-998-319, E-MTAB-998-320, E-MTAB-998-321, E-MTAB-998-322, E-MTAB-998-323, E-MTAB-998-324, E-MTAB-998-325, E-MTAB-998-326, E-MTAB-998-327, E-MTAB-998-328, E-MTAB-998-329, E-MTAB-998-330, E-MTAB-998-331, E-MTAB-998-332, E-MTAB-998-333, E-MTAB-998-334, E-MTAB-998-335, E-MTAB-998-336, E-MTAB-998-337, E-MTAB-998-338, E-MTAB-998-339, E-MTAB-998-340, E-MTAB-998-341, E-MTAB-998-342, E-MTAB-998-343, E-MTAB-998-344, E-MTAB-998-345, E-MTAB-998-346, E-MTAB-998-347, E-MTAB-998-348, E-MTAB-998-349, E-MTAB-998-350, E-MTAB-998-351, E-MTAB-998-352, E-MTAB-998-353, E-MTAB-998-354, E-MTAB-998-355, E-MTAB-998-356, E-MTAB-998-357, E-MTAB-998-358, E-MTAB-998-359, E-MTAB-998-360, E-MTAB-998-361, E-MTAB-998-362, E-MTAB-998-363, E-MTAB-998-364, E-MTAB-998-365, E-MTAB-998-366, E-MTAB-998-367, E-MTAB-998-368, E-MTAB-998-369, E-MTAB-998-370, E-MTAB-998-371, E-MTAB-998-372, E-MTAB-998-373, E-MTAB-998-374, E-MTAB-998-375, E-MTAB-998-376, E-MTAB-998-377, E-MTAB-998-378, E-MTAB-998-379, E-MTAB-998-380, E-MTAB-998-381, E-MTAB-998-382, E-MTAB-998-383, E-MTAB-998-384, E-MTAB-998-385, E-MTAB-998-386, E-MTAB-998-387, E-MTAB-998-388, E-MTAB-998-389, E-MTAB-998-390, E-MTAB-998-391, E-MTAB-998-392, E-MTAB-998-393, E-MTAB-998-394, E-MTAB-998-395, E-MTAB-998-396, E-MTAB-998-397, E-MTAB-998-398, E-MTAB-998-399, E-MTAB-998-400, E-MTAB-998-401, E-MTAB-998-402, E-MTAB-998-403, E-MTAB-998-404, E-MTAB-998-405, E-MTAB-998-406, E-MTAB-998-407, E-MTAB-998-408, E-MTAB-998-409, E-MTAB-998-410, E-MTAB-998-411, E-MTAB-998-412, E-MTAB-998-413, E-MTAB-998-414, E-MTAB-998-415, E-MTAB-998-416, E-MTAB-998-417, E-MTAB-998-418, E-MTAB-998-419, E-MTAB-998-420, E-MTAB-998-421, E-MTAB-998-422, E-MTAB-998-423, E-MTAB-998-424, E-MTAB-998-425, E-MTAB-998-426, E-MTAB-998-427, E-MTAB-998-428, E-MTAB-998-429, E-MTAB-998-430, E-MTAB-998-431, E-MTAB-998-432, E-MTAB-998-433, E-MTAB-998-434, E-MTAB-998-435, E-MTAB-998-436, E-MTAB-998-437, E-MTAB-998-438, E-MTAB-998-439, E-MTAB-998-440, E-MTAB-998-441, E-MTAB-998-442, E-MTAB-998-443, E-MTAB-998-444, E-MTAB-998-445, E-MTAB-998-446, E-MTAB-998-447, E-MTAB-998-448, E-MTAB-998-449, E-MTAB-998-450, E-MTAB-998-451, E-MTAB-998-452, E-MTAB-998-453, E-MTAB-998-454, E-MTAB-998-455, E-MTAB-998-456, E-MTAB-998-457, E-MTAB-998-458, E-MTAB-998-459, E-MTAB-998-460, E-MTAB-998-461, E-MTAB-998-462, E-MTAB-998-463, E-MTAB-998-464, E-MTAB-998-465, E-MTAB-998-466, E-MTAB-998-467, E-MTAB-998-468, E-MTAB-998-469, E-MTAB-998-470, E-MTAB-998-471, E-MTAB-998-472, E-MTAB-998-473, E-MTAB-998-474, E-MTAB-998-475, E-MTAB-998-476, E-MTAB-998-477, E-MTAB-998-478, E-MTAB-998-479, E-MTAB-998-480, E-MTAB-998-481, E-MTAB-998-482, E-MTAB-998-483, E-MTAB-998-484, E-MTAB-998-485, E-MTAB-998-486, E-MTAB-998-487, E-MTAB-998-488, E-MTAB-998

Data Curation

Happy RegExing!



```
19 extraction_scopes:
20   description: >-
21     Detection and processing of clinical scopes goes through several stages:
22     1. line cleanup - so far run for the input before processing the individual
23       scopes
24     2. line match using some general pattern expected in all lines containing
25       data for the current scope (`filter` pattern)
26     3. finding and extracting the relevant data by looping over a list of
27       specific patterns with memorized matches (`find`)
28     4. post-processing using empirical cleanup replacements (`cleanup`)
29     5. checking the correct structure (`final_check` - a global pattern can be
30       used if other post-processing is performed)
31
32
33 survival_status:
34   filter: '(?i).*?(?:(:deaf?:d|th))|alive|surviv|outcome|status'
35   preclean:
36     - m: '(?i)days to death or last seen alive[^w]+?\d+?(?:[^w\.]|$)'
37     s: ''
38     - m: '[^w]+?NA(?:[^w\.]|$)'
39     s: ''
40     - m: 'remission status past double induction .cr. complete remission. RD. refractory disease. ED. early death[^w]+?ED'
41     s: 'survival: dead'
42     - m: 'remission status past double induction .cr. complete remission. RD. refractory disease. ED. early death[^w]+?NA'
43     s: ''
44     - m: 'remission status past double induction .cr. complete remission. RD. refractory disease. ED. early death[^w]+?CR'
45     s: 'survival: alive'
46     - m: 'remission status past double induction .cr. complete remission. RD. refractory disease. ED. early death[^w]+?RD'
47     s: '# alive but not responding to therapy so removed?'
48     - m: 'Event Free Survival[^w]+?no event'
49     s: 'recurrence: no'
50     - m: 'Event Free Survival.event'
51     s: 'recurrence: yes'
52     - m: 'Outcome[^w]+?no event'
53     s: 'survival: alive'
54     - m: 'Outcome[^w]+?event'
55     s: 'survival: dead'
56     - m: 'survival status[^w]+?0'
57     s: 'survival: dead'
58     - m: 'survival status[^w]+?1'
59     s: 'survival: alive'
60     - m: 'overall[^w]+?survival[^w]+?days[^w]+?NA'
61     s: ''
62     - m: 'survival(?: time|from diagnosis)?[^w]+?(days|months|years?)[^w]+?(\\d\\d?\\d?\\d?\\.?\\d?\\d?)'
63     s: 'survival: \\2\\1'
```

Progenetix & arrayMap: Data Scopes

Biomedical and procedural "Meta"data types

- Diagnostic classification
 - mapping text-based cancer diagnoses to standard classification systems
- Provenance data
 - store identifier-based pointers
 - geographic attribution (individual, biosample, experiment)
- Clinical information
 - **core set** of typical cancer study values:
 - ➡ stage, grade, followup time, survival status, genomic sex, age at diagnosis
 - balance between annotation effort and expected usability



Disease annotations in Progenetix

From some text, somewhere, to ontology classes

- **diagnostic categories** are the **most important** labels to associate with genomic observations
- original data almost *never* uses **modern, hierarchical** classification systems but provides circumstantial ("breast cancer in pre-menopausal...") or domain-specific ("CLL Binet B", "colorectal carcinoma Dukes C") information
- clinical classifications (ICD-10 ...) have very limited relation to tumor biology
- concepts change over time ...
- for cancer, the "International Classification of Diseases in Oncology" (**ICD-O 3**) by IARC / WHO traditionally has been a good compromise to map to - but with non-hierarchical structure and is used by international reference projects

DX Ontologies

Hierarchical NCIt Neoplasm Core replaces heterogeneous primary annotations

- heterogeneous and inconsistent diagnostic annotations are common in clinical reports and research studies ("text", ICD-10, ICD-O 3, OncoTree, domain-specific classifications)
- highly **variable granularity** of annotations is a major road block for comparative analyses and large scale data integration
 - ▶ "Colorectal Cancer" or "Rectal Mucinous Adenoca."
- initiatives and services such as Phenopackets, MONDO, OXO ... rely on and/or provide mappings to hierarchical ontologies



NCIt Neoplasm Core coded display (excerpt) for samples in the Progenetix cancer genome data resource allows sample selection on multiple hierarchy levels →

	Subsets	Samples
□	▼ NCIT:C3262: Neoplasm	88844
□	▼ NCIT:C3263: Neoplasm by Site	84747
□	▼ NCIT:C156482: Genitourinary System Neoplasm	11616
□	▼ NCIT:C156483: Benign Genitourinary System Neoplasm	219
□	▼ NCIT:C4893: Benign Urinary System Neoplasm	90
□	▼ NCIT:C4778: Benign Kidney Neoplasm	90
□	NCIT:C159209: Kidney Leiomyoma	1
□	NCIT:C4526: Kidney Oncocytoma	82
□	NCIT:C8383: Kidney Adenoma	7
□	▼ NCIT:C7617: Benign Reproductive System Neoplasm	129
□	▼ NCIT:C4934: Benign Female Reproductive System Neoplasm	129
□	▼ NCIT:C2895: Benign Ovarian Neoplasm	58
□	▼ NCIT:C4510: Benign Ovarian Epithelial Tumor	58
□	▼ NCIT:C40039: Benign Ovarian Mucinous Tumor	58
□	NCIT:C4512: Ovarian Mucinous Cystadenoma	58
□	▼ NCIT:C4060: Ovarian Cystadenoma	58
□	NCIT:C4512: Ovarian Mucinous Cystadenoma	58
□	▼ NCIT:C3609: Benign Uterine Neoplasm	71
□	▼ NCIT:C3608: Benign Uterine Corpus Neoplasm	71
□	NCIT:C3434: Uterine Corpus Leiomyoma	71
□	▼ NCIT:C156484: Malignant Genitourinary System Neoplasm	11171
□	▼ NCIT:C157774: Metastatic Malignant Genitourinary System Neoplasm	2
□	▼ NCIT:C146893: Metastatic Genitourinary System Carcinoma	2
□	NCIT:C8946: Metastatic Prostate Carcinoma	2
□	▼ NCIT:C164141: Genitourinary System Carcinoma	10561
□	▼ NCIT:C146893: Metastatic Genitourinary System Carcinoma	2
□	NCIT:C8946: Metastatic Prostate Carcinoma	2
□	▼ NCIT:C3867: Fallopian Tube Carcinoma	19

Progenetix in 2022

Cancer Genomics Reference Resource

- largest open resource for curated cancer genome profiles
- >116'000 cancer CNV profiles, from >800 NCI codes
- majority of data from genomic arrays with ~50% overall from SNP platforms with original data re-processing
- structured diagnostic encodings for NCI, ICD-O 3, UBERON
- identifier mapping for PMID, GEO, Cellosaurus, TCGA, cBioPortal where appropriate
- core biosample and technical metadata annotations where accessible (TNM, genotypic sex, survival ...)
- publication database and code mapping services

Cancer CNV Profiles

- ICD-O Morphologies
- ICD-O Organ Sites
- Cancer Cell Lines
- Clinical Categories

Search Samples

arrayMap

- TCGA Samples
- 1000 Genomes Reference Samples
- DIPG Samples
- cBioPortal Studies
- Gao & Baudis, 2021

Publication DB

- Genome Profiling
- Progenetix Use

Services

- NCI Mappings
- UBERON Mappings

Upload & Plot

Beacon⁺

Documentation


- News
- Downloads & Use Cases
- Sevices & API

Baudisgroup @ UZH

Cancer genome data @ progenetix.org

The Progenetix database provides an overview of mutation data in cancer, with a focus on copy number abnormalities (CNV / CNA), for all types of human malignancies. The data is based on *individual sample data* from currently **142063** samples.


Floor of the Mouth Neoplasm (NCIT:C4401)



[Download SVG](#) | [Go to NCIT:C4401](#) | [Download CNV Frequencies](#)

Example for aggregated CNV data in 126 samples in Floor of the Mouth Neoplasm.
Here the frequency of regional **copy number gains** and **losses** are displayed for all 22 autosomes.

Progenetix Use Cases



Local CNV Frequencies

A typical use case on Progenetix is the search for local copy number aberrations - e.g. involving a gene - and the exploration of cancer types with these CNVs. The [\[Search Page \]](#) provides example use cases for designing queries. Results contain basic statistics as well as visualization and download options.

Cancer CNV Profiles

The progenetix resource contains data of **834** different cancer types (NCI neoplasm classification), mapped to a variety of biological and technical categories. Frequency profiles of regional genomic gains and losses for all categories (diagnostic entity, publication, cohort ...) can be accessed through the [\[Cancer Types \]](#) page with direct visualization and options for sample retrieval and plotting options.

Cancer Genomics Publications

Through the [\[Publications \]](#) page Progenetix provides **4164** annotated references to research articles from cancer genome screening experiments (WGS, WES, aCGH, cCGH). The numbers of analyzed samples and possible availability in the Progenetix sample collection are indicated.

Progenetix in 2022

Cancer Genomics Reference Resource

- largest open resource for curated cancer genome profiles
- >116'000 cancer CNV profiles, from >800 NCIt codes
- majority of data from genomic arrays with ~50% overall from SNP platforms with original data re-processing
- structured diagnostic encodings for NCIt, ICD-O 3, UBERON
- identifier mapping for PMID, GEO, Cellosaurus, TCGA, cBioPortal where appropriate
- core biosample and technical metadata annotations where accessible (TNM, genotypic sex, survival ...)
- publication database and code mapping services

progenetix

Search Samples Modify Query

Assembly: GRCh38 Chro: 9 Start: 21500001-21975098 End: 21967753-22500000
Type: DEL Filters: NCIT:C3058


progenetix

Samples: 668 Variants: 286 Calls: 675

Found Variants (.pgxseg) All Sample Variants (.json) All Sample Variants (.pgxseg) Show Variants in UCSC

UCSC region JSON Response Visualization options

Results Biosamples Biosamples Map Variants



progenetix: 670 samples


CC BY 4.0 progenetix.org (2021)

Matched Subset Codes	Subset Samples	Matched Samples	Subset Match Frequencies
UBERON:0002021	4	1	0.250
icdot-C71.4	4	1	0.250
icdom-94403	4291	664	0.155
NCIT:C3058	4375	664	0.152
UBERON:0016525	14	2	0.143
icdot-C71.1	14	2	0.143
UBERON:0000955	7068	651	0.092
icdot-C71.9	7066	651	0.092
icdom-94423	84	4	0.048
NCIT:C3796	84	4	0.048
UBERON:0001869	1712	14	0.008
icdot-C71.0	1712	14	0.008

Progenetix in 2022

Cancer Genomics Reference Resource

- largest open resource for curated cancer genome profiles
- >116'000 cancer CNV profiles, from >800 NCIt codes
- majority of data from genomic arrays with ~50% overall from SNP platforms with original data re-processing
- structured diagnostic encodings for NCIt, ICD-O 3, UBERON
- identifier mapping for PMID, GEO, Cellosaurus, TCGA, cBioPortal where appropriate
- core biosample and technical metadata annotations where accessible (TNM, genotypic sex, survival ...)
- publication database and code mapping services



Progenetix in 2022

Cancer Genomics Reference Resource

- contains special data subsets, identified using the "cohorts" concept
 - ▶ TCGA CNV data
 - ▶ 1000Genomes germline CNVs (WGS)
 - ▶ Cancer cell line CNVs with upcoming addition of annotated SNV ... data
 - ▶ cBioPortal studies
 - ▶ ...

TCGA CNV Data

Search Genomic CNV Data from TCGA

This search page accesses the TCGA subset of the Progenetix collection, based on 22142 samples (tumor and references) from The Cancer Genome Atlas project. The results are based upon data generated by the [TCGA Research Network](#). Disease-specific subsets of TCGA data (aka. projects) can be accessed below.

TCGA Cancer samples (pgx:cohort-TCGAcancers)

11090 samples

CC BY 4.0 progenetix.org (2022)

[Download SVG](#) | [Go to pgx:cohort-TCGAcancers](#) | [Download CNV Frequencies](#)

Edit Query

Publication DB

- Genome Profiling
- Progenetix Use

Services

- NCIt Mappings
- UBERON Mappings

Upload & Plot

Beacon⁺

Documentation

- News
- Downloads & Use Cases
- Sevices & API

TCGA Cancer Studies

Filter subsets e.g. by prefix Hierarchy Depth: 2 levels

No Selection

- pgx:TCGA-ACC: TCGA ACC project (180 samples)
- pgx:TCGA-BLCA: TCGA BLCA project (810 samples)
- pgx:TCGA-BRCA: TCGA BRCA project (2219 samples)
- pgx:TCGA-CESC: TCGA CESC project (586 samples)

Progenetix in 2022

Cancer Genomics Reference Resource

- contains special data subsets, identified using the "cohorts" concept
 - ▶ TCGA CNV data
 - ▶ 1000Genomes germline CNVs (WGS)
 - ▶ Cancer cell line CNVs with upcoming addition of annotated SNV ... data
 - ▶ cBioPortal studies
 - ▶ ...



Cancer CNV Profiles
ICD-O Morphologies
ICD-O Organ Sites
Cancer Cell Lines
Clinical Categories

Search Samples

arrayMap
TCGA Samples
1000 Genomes
Reference Samples
DIPG Samples
cBioPortal Studies
Gao & Baudis, 2021

Publication DB
Genome Profiling
Progenetix Use

Services
NCIt Mappings
UBERON Mappings

Upload & Plot

Beacon⁺


Documentation
News
Downloads & Use Cases
Sevices & API

1000 Genomes Germline CNVs

Search Genomic CNV Data from the Thousand Genomes Project

This search page accesses the reference germline CNV data of 3200 samples from the 1000 Genomes Project. The results are based on the data from the Illumina DRAGEN caller re-analysis of 3200 whole genome sequencing (WGS) samples downloaded from the AWS store of the Illumina-led reanalysis project.

1000 genomes reference samples (pgx:cohort-oneKgenomes)



Download SVG | Go to pgx:cohort-oneKgenomes | Download CNV Frequencies

Please note that the CNV spikes are based on the frequency of occurrence of any CNV in a given 1Mb interval, not on their overlap. Some genome bins may have at least one small CNV in each sample - especially in peri-centromeric regions - and therefore will display with a 100% frequency - although many of those may not overlap.

Search Samples

Range Example

Chromosome (Structural) Variant Type

Start or Position End (Range or Structural Var.)

Reference Base(s) Alternate Base(s)

Progenetix in 2022

Cancer Genomics Reference Resource

- largest open resource for curated cancer genome profiles
- >116'000 cancer CNV profiles, from >800 NCI codes
- majority of data from genomic arrays with ~50% overall from SNP platforms with original data re-processing
- structured diagnostic encodings for NCI, ICD-O 3, UBERON
- identifier mapping for PMID, GEO, Cellosaurus, TCGA, cBioPortal where appropriate
- core biosample and technical metadata annotations where accessible (TNM, genotypic sex, survival ...)
- publication database and code mapping services



[Cancer CNV Profiles](#)

[Search Samples](#)

[Studies & Cohorts](#)

[arrayMap](#)

[TCGA Samples](#)

[DIPG Samples](#)

[Gao & Baudis, 2021](#)

[Cancer Cell Lines](#)

[Publication DB](#)

[Genome Profiling](#)

[Progenetix Use](#)

[Services](#)

[NCI Mappings](#)

[UBERON Mappings](#)

[Upload & Plot](#)

[Download Data](#)

[Beacon⁺](#)

[Progenetix Info](#)

[About Progenetix](#)

Progenetix Publication Collection

The current page lists articles describing whole genome screening (WGS, WES, aCGH, cCGH) experiments in cancer, registered in the Progenetix publication collection. For each publication the table indicates the numbers of samples analysed with a given technology and if sample profiles are available in Progenetix.

Please [contact us](#) to alert us about additional articles you are aware of. The inclusion criteria are described in the documentation [↗](#).

New Oct 2021 You can now directly submit suggestions for matching publications to the [oncopubs](#) repository on [Github](#) [↗](#).


Filter [i](#)

City [i](#)

 Type to search... | [▼](#)

Publications (3349)

id i ▾	Publication	Samples				
		cCGH	aCGH	WES	WGS	pgx
PMID:34604048	Dai J, Jiang M, He K, Wang H, Chen P et al. (2021) DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and ... <i>Front Oncol</i>	0	0	122	0	0
PMID:34573430	Juhari WKW, Ahmad Amin Noordin KB et al. (2021) Whole-Genome Profiles of Malay Colorectal Cancer Patients with Intact MMR Proteins. ... <i>Genes (Basel)</i>	0	0	0	7	0
PMID:34307137	Xu S, Li X, Zhang H, Zu L, Yang L et al. (2021) Frequent Genetic Alterations and Their Clinical Significance in Patients With Thymic Epithelial ... <i>Front Oncol</i>	0	0	0	123	0



Ontologies and Classifications



Services: Ontologymaps (NCIt)

The **ontologymaps** service provides equivalency mapping between ICD-O and other classification systems, notably NCIt and UBERON. It makes use of the sample-level mappings for NCIT and ICD-O 3 codes developed for the individual samples in the Progenetix collection.

NCIT and ICD-O 3

While NCIT treats diseases as **histologic** and **topographic** described entities (e.g. [NCIT:C7700: Ovarian adenocarcinoma](#)), these two components are represented separately in ICD-O, through the **Morphology** and **Topography** coding arms (e.g. here [8140/3 + C56.9](#)).

More documentation with focus on the API functionality can be found on the [documentation pages](#).

The data of all mappings can be retrieved trough this API call: [{JSON ↗}](#)

Code Selection ⓘ

NCIT:C4337: Mantle Cell Lymphoma X | ▾

Optional: Limit with second selection | ▾

Matching Code Mappings [{JSON ↗}](#)

NCIT:C4337: Mantle Cell Lymphoma	pgx:icdom-96733: Mantle cell lymphoma	pgx:icdot-C77.9: Lymph nodes, NOS
NCIT:C4337: Mantle Cell Lymphoma	pgx:icdom-96733: Mantle cell lymphoma	pgx:icdot-C18.9: large intestine, excl. rectum and rectosigmoid junction
NCIT:C4337: Mantle Cell Lymphoma	pgx:icdom-96733: Mantle cell lymphoma	pgx:icdot-C42.2: Spleen

More than one code groups means that either mappings need refinements (e.g. additional specific NCIT classes for ICD-O T topographies) or you started out with an unspecific ICD-O M class and need to add a second selection.

In Progenetix all cancer diagnoses are coded to both NCIt neoplasm codes and ICD-O 3 Morphology + Topography combinations. The matched mappings are provided as lookup-service since neither an official ICD-O ontology nor such a "disease defined by ICD-O M+T" concept is codified anywhere.

List of filters recognized by different query endpoints

Public Ontologies with CURIE-based syntax

CURIE prefix	Code/Ontology	Examples
NCIT	NCIt Neoplasm ¹	NCIT:C27676
HP	HPO ²	HP:0012209
PMID	NCBI Pubmed ID	PMID:18810378
geo	NCBI Gene Expression Omnibus ³	geo:GPL6801, geo:GSE19399, geo:GSM491153
arrayexpress	EBI ArrayExpress ⁴	arrayexpress:E-MEXP-1008
cellosaurus	Cellosaurus - a knowledge resource on cell lines ⁵	cellosaurus:CVCL_1650
UBERON	Uberon Anatomical Ontology ⁶	UBERON:0000992
cBioPortal	cBioPortal ⁹	cBioPortal:msk_impact_2017

Private filters

Since some classifications cannot directly be referenced, and in accordance with the upcoming Beacon v2 concept of "private filters", Progenetix uses additionally a set of structured non-CURIE identifiers.

For terms with a `pgx` prefix, the [identifiers.org resolver](#) will


Filter prefix / local part	Code/Ontology	Example
pgx:icdom...	ICD-O 3 ⁷ Morphologies (Progenetix)	pgx:icdom-81703
pgx:icdot...	ICD-O 3 ⁷ Topographies(Progenetix)	pgx:icdot-C04.9
TCGA	The Cancer Genome Atlas (Progenetix) ⁸	TCGA-000002fc-53a0-420e-b2aa-a40a358bba37
pgx:pgxcohort...	Progenetix cohorts ¹⁰	pgx:pgxcohort-arraymap

Progenetix in 2022


Cancer Genomics Reference Resource

- largest open resource for curated cancer genome profiles
- >116'000 cancer CNV profiles, from >800 NCI codes
- majority of data from genomic arrays with ~50% overall from SNP platforms with original data re-processing
- structured diagnostic encodings for NCI, ICD-O 3, UBERON
- identifier mapping for PMID, GEO, Cellosaurus, TCGA, cBioPortal where appropriate
- core biosample and technical metadata annotations where accessible (TNM, genotypic sex, survival ...)
- publication database and code mapping services

Web Traffic



Web Traffic Requests by Country



Recent Publications

CNV Data Analysis & Methods

- collaborative projects utilizing the Progenetix data for multi-omics analyses
- data and bioinformatics analysis support for e.g. translational studies w/o "omics" focus



Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes

Bo Gao^{1,2} and Michael Baudis^{1,2*}

ORIGINAL RESEARCH
published: 13 May 2021
doi: 10.3389/fgene.2021.654887



ORIGINAL PAPER

CNARA: reliability assessment for genomic copy number profiles

Ni Ai^{1*}, Haoyang Cai², Caius Solovan³ and Michael Baudis^{1*}

Ai et al. *BMC Genomics* (2016) 17:799
DOI 10.1186/s12864-016-3074-7



Cai et al. *BMC Genomics* 2
<http://www.biomedcentral.com>

Contents lists available at [ScienceDirect](#)

Genomics

journal homepage: www.elsevier.com/locate/ygeno



RESEARCH ARTICLE
Minimum error calibration and normalization for genomic copy number analysis

Bo Gao^{a,b}, Michael Baudis^{a,b,*}


Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens

Haoyang Cai^{1,2}, Nitin Kumar^{1,2}, Homayoun C Bagheri³, Christian von Mering^{1,2}, Mark D Robinson^{1,2*}
and Michael Baudis^{1,2*}


SOFTWARE TOOL ARTICLE


REVISED
segment_liftover : a Python tool to convert segments between genome assemblies [version 2; peer review: 2 approved]

Bo Gao^{1,2}, Qingyao Huang^{1,2}, Michael Baudis^{1,2}


OPEN
Enabling population assignment from cancer genomes with SNP2pop

Qingyao Huang^{1,2} & Michael Baudis^{1,2*}




Crossmark

ORIGINAL PAPER

Enabling population assignment from cancer genomes with SNP2pop

Qingyao Huang^{1,2} & Michael Baudis^{1,2*}

The Progenetix oncogenomic resource in 2021

Qingyao Huang^{1,2}, Paula Carrio-Cordo^{1,2}, Bo Gao^{1,2}, Rahel Paloots^{1,2} and Michael Baudis^{1,2,*}

¹Department of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, Zurich 8057, Switzerland

²Swiss Institute of Bioinformatics, Winterthurerstrasse 190, Zurich 8057, Switzerland

*Corresponding author: Tel: +41 44 635 34 86; Email: michael.baudis@mls.uzh.ch

Citation details: Huang, Q., Carrio-Cordo, P., Gao, B. et al. The Progenetix oncogenomic resource in 2021. *Database* (2021) Vol. 2021: article ID baab043; DOI: <https://doi.org/10.1093/database/baab043>

Abstract

In cancer, copy number aberrations (CNAs) represent a type of nearly ubiquitous and frequently extensive structural genome variations. To disentangle the molecular mechanisms underlying tumorigenesis as well as identify and characterize molecular subtypes, the comparative and meta-analysis of large genomic variant collections can be of immense importance. Over the last decades, cancer genomic profiling projects have resulted in a large amount of somatic genome variation profiles, however segregated in a multitude of individual studies and datasets. The Progenetix project, initiated in 2001, curates individual cancer CNA profiles and associated metadata from published oncogenomic studies and data repositories with the aim to empower integrative analyses spanning all different cancer biologies. During the last few years, the fields of genomics and cancer research have seen significant advancement in terms of molecular genetics technology, disease concepts, data standard harmonization as well as data availability, in an increasingly structured and systematic manner. For the Progenetix resource, continuous data integration, curation and maintenance have resulted in the most comprehensive representation of cancer genome CNA profiling data with 138 663 (including 115 357 tumor) copy number variation (CNV) profiles. In this article, we report a 4.5-fold increase in sample number since 2013, improvements in data quality, ontology representation with a CNV landscape summary over 51 distinctive National Cancer Institute Thesaurus cancer terms as well as updates in database schemas, and data access including new web front-end and programmatic data access.

Database URL: progenetix.org

Table 1. Statistics of samples from various data resources

Data source	GEO	ArrayExpress	cBioPortal	TCGA	Total
No. of studies	898	51	38	33	1939
No. of samples	63 568	4351	19 712	22 142	138 663
Tumor	52 090	3887	19 712	11 090	115 357
Normal	11 478	464	0	11 052	23 306
Classifications					
ICD-O (Topography)	100	54	88	157	209
ICD-O (Morphology)	246	908	265	140	491
NCIt	346	148	422	182	788
Collections					
Individuals	63 568	4351	19 712	10 995	127 549
Biosamples	63 568	4351	19 712	22 142	138 663
Callsets ^a	63 568	4351	19 712	22 376	138 930
Variants	5 514 126	118 4170	1 778 096	2 654 065	10 716 093

^aset of variants from one genotyping experiment; ICD-O, International Classification of Diseases for Oncology; NCIt, National Cancer Institute Thesaurus.





Figure 3. Beacon-style query using fuzzy ranges to identify biosamples with variants matching the CNA range. This example queries for a continuous, focal duplication covering the complete MYC gene's coding region with ≤ 6 Mb in size. A: Filter for dataset; B: filter for cancer classification (NCIt and ICD-O-3 ontology terms available); C: additional filter, e.g. Cellosaurus; D: additional filter for geographic location; E: external link to UCSC browser to view the alignment of matched variants; F: cancer type classification sorted by frequency of the matched biosamples present in the subset; G: list of matched variants with reference to biosamples can be downloaded in json or csv format.



Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes

Bo Gao^{1,2} and Michael Baudis^{1,2*}




FIGURE 1 | The workflow of the study was composed of three parts. The *Features* part consisted of methods of data integration and feature generation. The *Signature* part focused on creating CNA signatures for cancer subtypes and the categorization of subtypes. The *Classification* part recruited machine learning techniques to predict the organ and the subtype from a given copy number profile.




FIGURE 5 | A clustering heatmap of features in 31 signatures. Columns are normalized average CNV intensities of feature genes, where the blue colors are duplication features and red colors are deletion features. Duplication and deletion frequencies are normalized separately.





FIGURE 6 | The integrated view of the original data and the selected features, in the neural crest originating entities medulloblastoma, glioma, and melanoma. The shaded background area color illustrates the original data. Color bars illustrate the feature genes, where brighter colors indicate stronger signal intensity. The blue colors above the chromosome axis represent the average amplifications, and the red colors below the chromosome axis represent the average deletions. The amplitude of amplifications and deletions are normalized to [0,1] separately. The adjacent known driver genes are also included for each tumor type.

Number of tumor samples for each publication across the years



Map of the geographic distribution (by first author affiliation) of the 104'543 genomic array, 36'766 chromosomal CGH and 15'409 whole genome/exome based cancer genome datasets.

The numbers are derived from the 3'240 publications registered in the Progenetix database.



Progenetix Publication Collection

The current page lists articles describing whole genome screening (WGS, WES, aCGH, cCGH) experiments in cancer, registered in the Progenetix publication collection. For each publication the table indicates the numbers of samples analysed with a given technology and if sample profiles are available in Progenetix.



Please [contact us](#) to alert us about additional articles you are aware of. The inclusion criteria are described in the documentation [🔗](#).

Filter [i](#) City [i](#)

 Type to search... [▼](#)

Publications (3324)

id i ▾	Publication	cCGH	aCGH	WES	WGS	pgx
PMID:34103027	Peng G, Chai H, Ji W, Lu Y, Wu S et al. (2021) Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of ... <i>BMC Med Genomics</i>	0	79	0	0	0
PMID:34059130	Tsui DWY, Cheng ML, Shady M, Yang JL et al. (2021) Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. ... <i>bioRxiv</i>	0	0	5	113	0



Progenetix Needs & Offers

What we have ...

- ✓ collection of >4000 articles assessed for scope
 - training set for NLP & search engine generation
- ✓ cancer specific ontologies with cross-mappings (ICD-O vs. NCIt) based on >100k samples
 - existing service API
- ✓ metadata ontology mappings for some 10k samples, with varying coverage for grade / stage / survival / ...
- ✓ CNV profiles for >110k samples, >700 entities with disease codes and metadata
- ✓ cell line CNV profiles together with mapped variants with clinical evidences


What we're working on...

- (semi-)automated detection of additional articles for scope (genome screening technologies, cancer samples, geographies)
- generation of a complete ICD-O terminology tree with NCIT (?) correspondence
 - improved service API & publication
- improved annotations using smarter source (article, annotation files) pre-/processing
- correlation between individual profiles, profile heterogeneity and external parameters
- relation between cell lines and native tumor types, with consideration of non-CNV parameters and publication use



First Implementation Study and Ongoing Work


Michael Baudis | ELIXIR Human Data Communities | 2022-03-15



Why hCNV Community?

Structural Genome Variation Data :: Resources and Technologies

- structural genome variations are a major contributor to genetic diseases and cancer
- knowledge about and standards for copy number variations / aberrations (CNV/CNA) has not been in step with NGS & GWAS driven SNV/SNP assessment



CNV with unknown clinical impact in a case of Silver-Russel Syndrome

Local Affymetrix Genotyping 6 signal distribution pattern and segmentation result in patient SR12 (SR0012, orange data) and his father (SR0012V, steelblue data). In both samples a duplication in the DSCR can be observed, affecting the whole KCNE1 and DSCR1/RCAN coding regions. In contrast, DYRK1A lays ~2.5 Mb distal of the duplication. Only the genes discussed in this article are shown.

Mission statement

Despite the fact that **Copy Number Variations** are the **most prevalent genetic mutation type**, identifying and interpreting them is still a major challenge. The ELIXIR human Copy Number Variation (hCNV) Community aims to implement processes to make the **detection**, **annotation** and **interpretation** of these variations easier

RESEARCH ARTICLE

AMERICAN JOURNAL OF
medical genetics PART
A

Identification of a 21q22 Duplication in a Silver–Russell Syndrome Patient Further Narrows Down the Down Syndrome Critical Region

Thomas Eggermann,^{1,*} Nadine Schönherr,¹ Sabrina Spengler,¹ Susanne Jäger,¹ Bernd Denecke,² Gerhard Binder,³ and Michael Baudis⁴

¹Institute of Human Genetics, RWTH Aachen, Aachen, Germany

²Interdisciplinary Centre for Clinical Research, IZKF "BIOMAT," RWTH Aachen, Aachen, Germany

³Section of Paediatric Endocrinology and Diabetology, University Children's Hospital, Tuebingen, Germany

⁴Institute of Molecular Biology, University of Zürich, Zürich, Switzerland

Received 26 June 2009; Accepted 6 November 2009



hCNV Implementation Study 2019-2021

Some Achievements and Deliveries

- HGVS satellite meeting – Human CNV – June 14th 2019 – Göteborg Sweden
- hCNV community workshop ELIXIR All-Hands Lisbon – June 2019
- survey of data annotation formats, including comments on VCF development
- start FAIRification of CNV national / reference databases (BANCCO, Progenetix)
- Community white paper published
- Biohackathon Paris 2019
- in 2021 start of shared meetings of subgroup with Beacon variants scout team

F1000Research

F1000Research 2020, 9(ELIXIR):1229 Last updated: 01 JUN 2021



OPINION ARTICLE

The ELIXIR Human Copy Number Variations Community: building bioinformatics infrastructure for research [version 1; peer review: 1 approved]

David Salgado ¹, Irina M. Armean², Michael Baudis ³, Sergi Beltran^{4,5}, Salvador Capella-Gutierrez ^{6,7}, Denise Carvalho-Silva ^{8,2,8}, Victoria Dominguez Del Angel ⁹, Joaquin Dopazo ¹⁰, Laura I. Furlong ¹¹, Bo Gao ¹², Leyla Garcia ^{12,13}, Dietlind Gerloff¹⁴, Ivo Gut^{4,5}, Attila Gyenessei¹⁵, Nina Habermann¹⁶, John M. Hancock ¹³, Marc Hanauer¹⁷, Eivind Hovig ^{18,19}, Lennart F. Johansson²⁰, Thomas Keane², Jan Korbel¹⁶, Katharina B. Lauer ¹³, Steve Laurie⁴, Brane Leskošek²¹, David Lloyd ¹³, Tomas Marques-Bonet²², Hailiang Mei²³, Katalin Monostory²⁴, Janet Piñero ¹¹, Krzysztof Poterlowicz ²⁵, Ana Rath¹⁷, Pubudu Samarakoon²⁶, Ferran Sanz¹¹, Gary Saunders ¹³, Daoud Sie²⁷, Morris A. Swertz²⁰, Kirill Tsukanov ¹², Alfonso Valencia^{6,7,28}, Marko Vidak²¹, Cristina Yenyxe González², Bauke Ylstra²⁹, Christophe Béroud^{1,30}

¹Aix Marseille Univ, INSERM, MMG, Marseille, France

²European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, UK

³Department of Molecular Life Sciences and Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland

⁴CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Baldri Reixac 4, Barcelona 08028, Spain

⁵Universitat Pompeu Fabra (UPF), Barcelona, Spain

⁶Barcelona Supercomputing Center (BSC), Barcelona, Spain

⁷Spanish National Bioinformatics Institute (INB)/ELIXIR-ES, Barcelona, Spain

⁸Open Targets, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK

⁹Institut Français de Bioinformatique, UMS3601-CNRS, CNRS, Paris, France

¹⁰Clinical Bioinformatics Area, Fundación Progreso y Salud, CDCA, Hospital Virgen del Rocío, Sevilla, Spain

¹¹Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Department of Experimental and Health Sciences, Pompeu Fabra University (UPF), Barcelona, Spain

¹²ZB MED Information Centre for Life Sciences, Cologne, Germany

¹³ELIXIR Hub, Hinxton, UK

¹⁴Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, Luxembourg

¹⁵Szentágóthai Research Center, University of Pécs, Pécs, Hungary

¹⁶Genome Biology, European Molecular Biological Laboratory, Heidelberg, Germany

¹⁷Orphanet, INSERM, Paris, France

¹⁸Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

¹⁹Centre for bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway

²⁰Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

²¹Faculty of Medicine - ELIXIR Slovenia, University of Ljubljana, Ljubljana, Slovenia

²²Institute of Evolutionary Biology (UPF-CSIC), Catalan Institution for Research and Advanced Studies, Barcelona, Spain

²³Sequencing Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands

²⁴Institute of Enzymology, Research Centre for Natural Sciences, Budapest, Hungary

²⁵Centre for Skin Sciences, University of Bradford, Bradford, UK



hCNV Implementation Studies 2021-2023

Focus on Integration with ELIXIR Platforms and Communities - and beyond

- original 2019-2021 implementation study provided visibility and established connections for new studies
- instrumental were Biohackathons, use case & standards surveys and co-participation of group members
- future work plans to leverage the resources of participants through pre-established interactions and synergies
- 2 independent studies provide clearer definitions of deliverables and individual scopes



Michael Baudis	CH
Christophe Béroud	FR
David Salgado	FR
Alexander Kanitz	CH
Anthony Brookes	UK
Babita Singh	ES
Björn Grüning	DE
Jordi Rambla	ES
Kirill Tsukanov	EMBL-EBI
Krzysztof Poterlowicz	UK
Salvador Capella-Gutierrez	ES
Sergi Beltran	ES
Steven Laurie	ES
Tim Beck	UK
Timothée Cezard	EMBL-EBI



Ongoing... hCNV & Intl. Community

- contributions to ontologies and standard definitions
- close ongoing interactions with GA4GH work streams
- influencing the development of the GA4GH VRS variant standard

hCNV Community

Genomic Copy Number Variations in Humans

News & Events

ELIXIR All Hands 2022 - h-CNV Representation
[CNV Ontology Proposal - Now Live at EFO](#)
[hCNV Site now at cnvar.org](#)
[hCNV Implementation Study 2021/2: Beacon and Beyond all ...](#)

Participants

[Standards and Guidelines](#)
[Studies & Resources](#)
[Examples, Guides & FAQ](#)
[Contacts](#)

Related Sites

[h-CNV @ ELIXIR](#)
[Beacon Project](#)
[Beacon @ ELIXIR](#)
[SchemaBlocks](#)

Github Projects

[h-CNV](#)

CNV Ontology Proposal - Now Live at EFO

As part of the hCNV-X work - related to "Workflows and Tools for hCNV Data Exchange Procedures" and to the intersection with Beacon and GA4GH VRS - we have now a [new proposal](#) for the creation of an ontology for the annotation of (relative) CNV events. The CNV representation ontology is targeted for adoption by Sequence Ontology (SO) and then to be used by an updated version of the VRS standard. Please see the discussions linked from the [proposal page](#). However, we have also contributed the CNV proposal to EFO where it has gotten live on January 21.

Everybody is welcome to contribute to the editing of the proposal at the SO & VRS Github repositories!

2021-01-21: copy number assessment term tree now live on EFO

The [copy number assessment](#) term tree has been accepted into the Experimental Factor Ontology and can be used for referencing CNV types.

More ontologies...

... with h-CNV contributions ca

2022-01-21

larrybabb commented 18 days ago

per a discussion between @ahwagner and @larrybabb
Draft Relative Copy Number class proposal

```
-- the target region/gene/feature
subject: region/gene/feature/allele/haplotype

--5 quantifiable values that correspond to the EFO copy number assessment
copy number assessment: (http://www.ebi.ac.uk/efo/EFO\_0030063)
-2 = complete loss (http://www.ebi.ac.uk/efo/EFO\_0030069)
-1 = partial loss (http://www.ebi.ac.uk/efo/EFO\_0030068)
0 = copy-neutral (http://www.ebi.ac.uk/efo/EFO\_0030064)
1 = low-level gain (http://www.ebi.ac.uk/efo/EFO\_0030071)
2 = high-level gain(http://www.ebi.ac.uk/efo/EFO\_0030072)
```

RelativeCopyNumber

Relative Copy Number Variation captures a classification of copies of a molecule within a system, relative to a baseline. These types of Variation are common outputs from CNV callers, particularly in the somatic domain where Absolute Copy Counts are difficult to estimate and less useful in practice than relative statements.

Computational Definition

The relative copies of a [Molecular Variation](#), [Feature](#), [Sequence Expression](#), or a [CURIE](#) reference against an unspecified baseline in a system (e.g. genome, cell, etc.).

Information Model

Some RelativeCopyNumber attributes are inherited from [Variation](#).

Field	Type	Limits	Description
_id	CURIE	0..1	Variation Id. MUST be unique within document.
type	string	1..1	MUST be "RelativeCopyNumber"
subject	Molecular Variation Feature Sequence Expression CURIE	1..1	Subject of the Copy Number object
relative_copy_class	string	1..1	MUST be one of "complete loss", "partial loss", "copy neutral", "low-level gain" or "high-level gain".

```

graph TD
    A[experimental factor] --> B[information entity]
    B --> C[copy number assessment]
    C --> D[regional base ploidy]
    C --> E[copy-neutral loss of heterozygosity]
    C --> F[relative copy number variation]
    F --> G[copy number gain]
    G --> H[high-level copy number gain]
    G --> I[focal genome amplification]
    G --> J[low-level copy number gain]
    F --> K[copy number loss]
    K --> L[complete genomic deletion]
    K --> M[low-level copy number loss]
  
```

EFO Experimental Factor Ontology

Global Alliance for Genomics & Health

Progenetix and GA4GH Beacon

Implementation driven development of a GA4GH standard




The vision: Federation of data





Global Alliance for Genomics & Health

Collaborate. Innovate. Accelerate.



Enabling responsible genomic data sharing for the benefit of human health

The Global Alliance for Genomics and Health (GA4GH) is a policy-framing and technical standards-setting organization, seeking to enable responsible genomic data sharing within a **human rights framework**.

The Global Alliance for Genomics and Health

Making genomic data accessible for research and health

- January 2013 - 50 participants from eight countries
- June 2013 - White Paper, over next year signed by 70 “founding” member institutions (e.g. SIB, UZH)
- March 2014 - Working group meeting in Hinxton & 1st plenary in London
- October 2014 - Plenary meeting, San Diego; interaction with ASHG meeting
- June 2015 - 3rd Plenary meeting, Leiden
- September 2015 - GA4GH at ASHG, Baltimore
- October 2015 - DWG / New York Genome Centre
- April 2016 - Global Workshop @ ICHG 2016, Kyoto
- October 2016 - 4th Plenary Meeting, Vancouver
- May 2017 - Strategy retreat, Hinxton
- October 2017 - 5th plenary, Orlando
- May 2018 - Vancouver
- October 2018 - 6th plenary, Basel
- May 2019 - GA4GH Connect, Hinxton
- October 2019 - 7th Plenary, Boston
- October 2020 - Virtual Plenary, June 2021 - Virtual Connect ...
- October 2021 - Virtual Plenary ...
- September 2022 - 10th Plenary, Barcelona


GENOMICS

A federated ecosystem for sharing genomic, clinical data

Silos of genome data collection are being transformed into seamlessly connected, independent systems

The Global Alliance for Genomics
and Health*

SCIENCE 10 JUNE 2016 • VOL 352 ISSUE 6291



22 SEPTEMBER 2022 | BARCELONA, SPAIN

GA4GH 10th Plenary





GENOMICS

A federated ecosystem for sharing genomic, clinical data

Silos of genome data collection are being transformed into seamlessly connected, independent systems

A federated data ecosystem. To share genomic data globally, this approach furthers medical research without requiring compatible data sets or compromising patient identity.






Beacon

A **Beacon** answers a query for a specific genome variant against individual or aggregate genome collections

YES | NO | \0



Have you seen this variant?
It came up in my patient
and we don't know if this is
a common SNP or worth
following up.

A Beacon network federates
genome variant queries
across databases that
support the **Beacon API**

Here: The variant has
been found in **few**
resources, and those
are from **disease**
specific **collections**.

Introduction

... I proposed a challenge application for all those wishing to seriously engage in *international* data sharing for human genomics. ...

1. Provide a public web service
2. Which accepts a query of the form “Do you have any genomes with an “A” at position 100,735 on chromosome 3?”
3. And responds with one of “Yes” or “No” ...

“Beacon” because ... people have been scanning the universe of human research for *signs of willing participants in far reaching data sharing*, but ... it has remained a dark and quiet place. The hope of this challenge is to 1) *trigger the issues* blocking groups ... in way that isn’t masked by the ... complexities of the science, fully functional interfaces, and real issues of privacy, and to 2) in *short order* ... see *real beacons of measurable signal* ... from *at least some sites* ... Once your “GABeacon” is shining, you can start to take the *next steps to add functionality* to it, and *finding the other groups* ... following their GABeacons.

Utility

Some have argued that this simple example is not “useful” so nobody would build it. Of course it is not the first priority for this application to be scientifically useful. ...intended to provide a *low bar for the first step of real ... engagement*. ... there is some utility in ...locating a rare allele in your data, ... not zero.

A number of more useful first versions have been suggested.

1. Provide *frequencies of all alleles* at that point
2. Ask for all alleles seen in a gene *region* (and more elaborate versions of this)
3. Other more complicated queries




"I would personally recommend all those be held for
version 2, when the beacon becomes a service."
Jim Ostell, 2014

Implementation

1. Specifying the chromosome ... The interface needs to specify the *accession.version* of a chromosome, or *build number*...
2. Return values ... right to *refuse* to answer without it being an error ... DOS *attack* ... or because ...especially *sensitive*...
3. Real time response ... Some sites suggest that it would be necessary to have a “*phone home*” response ...

Beacon+ in 2016 - Driving GA4GH implementations



ELIXIR - Making Beacons Biomedical



- Authentication to enable non-aggregate, patient derived datasets
 - ELIXIR AAI with compatibility to other providers (OAuth...)
 - Scoping queries through "biodata" parameters
 - Extending the queries towards clinically ubiquitous variant formats
 - cytogenetic annotations, named variants, variant effects
- Beacons as part of local, secure environments
 - local EGA ...
- Beacon queries as entry for **data delivery**
 - handover to stream and download using htsget, VCF, EHRs
- Interacting with EHR standards
 - FHIR translations for queries and handover ...

This forward looking Beacon interface implements additional, planned features.

Query

Dataset	tcga
Reference name*	9
Genome Assembly*	GRCh38 / hg38
Start min Position*	19,500,000
Start max Position	21,975,098
End min Position	21,967,753
End max Position	24,500,000
Alt. Base(s)*	DEL
Bio-ontology	icdot:c50.9: (4065)

Beacon Implementations

- implementing existing resources with Beacon protocol
- e.g. TCGA cancer variants (structural and SNV)

Beacon Response

- quantitative (counts for variants, callsets and samples)
- *Handover* to authentication system for data retrieval
- **no exposure** of data beyond standard Beacon response and additional pointer to matched data

Prototyping Query Extensions


- testing e.g. bio-metadata queries using ontology terms

Dataset	Assembly	Chro	Start Range	End Range	Pos	Ref Alt	Bio Query	Variants Calls Samples	f_alleles	Response Context
tcga	hg38	9	19,500,000 21,975,098	21,967,753 24,500,000		DEL	icdot:c50.9:	54 54 54	0.0243	JSON UCSC Handover

arrayMap progenetix This Beacon implementation is developed by the Computational Oncogenomics Group at the University of Zurich, with support from the SIB Technology group and ELIXIR.

Beacon & Handover

Beacons v1.1
supports data
delivery services



Michael Baudis



University of
Zurich UZH





This example shows a core Beacon query, against a specific mutation in the TP53 gene, in cellosaurus, with ClinVar data.

CNV Example SNV Range Example SNV Example ClinVar Example Beacon Help

Dataset*

arraymap
progenetix
cellosaurus
dipg
BeaconSpecTest2
BeaconSpecTest

Genome Assembly*

GRCh38 / hg38

Dataset Responses

All Selected Datasets

Reference name*

17

Gene Coordinates

TP53

Cytoband(s)

17p13.1

Start

7673767

Ref. Base(s)

C

Alt. Base(s)

T

Bio-ontology

no selection
NCIT:C102872: Pharyngeal squamous cell carcinoma (2)
NCIT:C103968: Pyruvate dehydrogenase deficiency (1)
NCIT:C105555: High grade ovarian serous adenocarcinoma (75)
NCIT:C105556: Low grade ovarian serous adenocarcinoma (10)
NCIT:C111802: Dyskeratosis congenita (3)

Other Filters

additional comma-separated, prefixed filters

Beacon Query

Beacon+

Flexible Modeling of New Features

Our Beacon platform is being used for the rapid testing of queries and responses - both v1.n and v2.0.a - against a number of partially large-scale genome datasets.

- Progenetix (>100000 cancer CNV profiles)
- DIPG (childhood brain tumor study)
- NEW: Cellosaurus ClinVar annotations for evidence representation
- Brewing: COVID-19

Currently running on a Perl+MongoDB stack, a Python-based OS solution is in early development.




```
{
  "callset_id": "cs-cellosaurus:CVCL_EI02",
  "info": {
    "cellosaurus": {
      "cell_line": "BT474-LAPRa",
      "id": "CVCL_EI02",
      "cellosaurus_variant_name": "TP53 p.Glu285Lys (c.853G>A)"
    },
    "clinvar": {
      "gene_id": "7157",
      "allele_id": "410258",
      "assembly": "GRCh38",
      "cytoband": "17p13.1",
      "variant_type": "single nucleotide variant",
      "origin": "germline;somatic",
      "phenotype": "Hereditary cancer-predisposing syndrome;Li-Fraumeni syndrome;PARP Inhibitor response;not provided",
      "clinical_significance": "Pathogenic/Likely pathogenic",
      "clinvar_full_name": "NM_001126112.2(TP53):c.853G>A (p.Glu285Lys)"
    },
    "start_min": 7673766,
    "reference_name": "17",
    "end_min": 7673767,
    "biosample_id": "bios-cellosaurus:CVCL_EI02",
    "alternate_bases": [
      "T"
    ],
    "digest": "17_7673767_C_T",
    "reference_bases": "C",
    "variantset_id": "cellosaurus_clinvar_GRCH38",
    "end_max": 7673767,
    "start_max": 7673766
  },
  "{
    "digest": "17_7673767_C_T",
    "reference_bases": "C",
    "alternate_bases": [
      "T"
    ],
    "variantset_id": "cellosaurus_clinvar_GRCH38",
    "end_max": 7673767,
    "start_max": 7673766,
    "callset_id": "cs-cellosaurus:CVCL_AQ07",
    "start_min": 7673766,
    "info": {
      "cellosaurus": {
        "cellosaurus_variant_name": "TP53 p.Glu285Lys (c.853G>A)",
        "cell_line": "BT-474 Clone 5",
        "id": "CVCL_AQ07"
      },
      "clinvar": {
        "assembly": "GRCh38",
        "allele_id": "410258",
        "gene_id": "7157",
        "cytoband": "17p13.1",
        "variant_type": "single nucleotide variant",
        "phenotype": "Hereditary cancer-predisposing syndrome;Li-Fraumeni syndrome;PARP Inhibitor response;not provided",
        "origin": "germline;somatic",
        "clinvar_full_name": "NM_001126112.2(TP53):c.853G>A (p.Glu285Lys)",
        "clinical_significance": "Pathogenic/Likely pathogenic"
      },
      "end_min": 7673767,
      "biosample_id": "bios-cellosaurus:CVCL_AQ07",
      "reference_name": "17"
    },
    "{
      "alternate_bases": [
        "T"
      ],
      "reference_bases": "C",
      "digest": "17_7673767_C_T",
      "end_max": 7673767,
      "variantset_id": "cellosaurus_clinvar_GRCH38",
      "start_max": 7673766,
      "callset_id": "cs-cellosaurus:CVCL_AQ07",
      "start_min": 7673766
    }
  }
}
```

Progenetix in 2022

Variant and Metadata for Sample Discovery

- positional queries for genomic variants using the **GA4GH Beacon protocol**
- metadata queries (diagnoses, identifiers, clinical classes ...) using **Beacon "filters"**



progenetix

Cancer CNV Profiles

Search Samples

Studies & Cohorts

- arrayMap
- TCGA Samples
- DIPG Samples
- Gao & Baudis, 2021
- Cancer Cell Lines

Publication DB

Services

- NCIt Mappings
- UBERON Mappings

Upload & Plot

Download Data

Beacon+

Progenetix Info

- About Progenetix
- Use Cases
- Documentation
- Baudisgroup @ UZH

Search Samples

CDKN2A Deletion Example MYC Duplication TP53 Del. in Cell Lines K-562 Cell Line

Gene Spans Cytoband(s)

This example shows the query for CNV deletion variants overlapping the CDKN2A gene's coding region with at least a single base, but limited to "highly focal" hits (here i.e. $\leq \sim 1\text{Mbp}$ in size). The query can be modified e.g. through changing the position parameters or diagnosis.

Gene Symbol i

Select...

Chromosome i

9

(Structural) Variant Type i

DEL (Deletion)

Start or Position i

21500001-21975098

End (Range or Structural Var.) i

21967753-22500000

Minimum Variant Length i

Maximal Variant Length i

Reference ID(s) i

Select...

Cancer Classification(s) i

NCIT:C3058: Glioblastoma (4375) x

Clinical Classes i

Select...

Genotypic Sex i

Select...

Biosample Type i

Select...

Filters i 🔗

Filter Logic i

AND

Filter Precision i

exact

City i

Select...

Chromosome 9 i

21500001-21975098

21967753-22500000

Query Database

Beacon v1 Development

2014

GA4GH founding event; Jim Ostell proposes Beacon concept including "more features ... version 2"

2015

- beacon-network.org aggregator created by DNAstack

2016

- Beacon v0.3 release
- work on queries for structural variants (brackets for fuzzy start and end parameters...)

2017

- OpenAPI implementation
- integrating CNV parameters (e.g. "startMin, statMax")

2018

- Beacon v0.4 release in January; feature release for GA4GH approval process
- GA4GH Beacon v1 approved at Oct plenary

2019

- ELIXIR Beacon Network

2020

Beacon v2 Development

- Beacon⁺ concept implemented on progenetix.org
- concepts from GA4GH Metadata (ontologies...)
- entity-scoped query parameters ("individual.age")

- Beacon⁺ demos "handover" concept

- Beacon hackathon Stockholm; settling on "filters"
- Barcelona goes Zurich developers meeting
- Beacon API v2 Kick off
- adopting "handover" concept
- "Scouts" teams working on different aspects - filters, genomic variants, compliance ...
- discussions w/ clinical stakeholders

- framework + models concept implemented
- range and bracket queries, variant length parameters
- starting of GA4GH review process
- further changes esp. in default model, aligning with Phenopackets and VRS
- unified beacon-v2 code & docs repository
- Beacon v2 approved at Apr GA4GH Connect

2022

Related ...

- ELIXIR starts Beacon project support
- GA4GH re-structuring (workstreams...)
- Beacon part of Discovery WS
- new Beacon website (March)
- Beacon publication at Nature Biotechnology
- docs.genomebeacons.org

Beacon v1 Development

2014

GA4GH founding event; Jim Ostell proposes Beacon concept including "more features ... version 2"

2015

- beacon-network.org aggregator created by DNAstack

2016

- Beacon v0.3 release
 - work on queries for structural variants (brackets for fuzzy start and end parameters...)

2017

- OpenAPI implementation
- integrating CNV parameters (e.g. "startMin, statMax")

2018

- Beacon v0.4 release in January; feature release for GA4GH approval process
- GA4GH Beacon v1 approved at Oct plenary

2019

- ELIXIR Beacon Network

2020

2021

2022

Beacon v2 Development

Related ...

- ELIXIR starts Beacon project support

- GA4GH re-structuring (workstreams...)
- Beacon part of Discovery WS

- new Beacon website (March)

- Beacon publication at Nature Biotechnology

- Phenopackets v2 approved

- docs.genomebeacons.org

- Beacon+ concept implemented on progenetix.org
- concepts from GA4GH Metadata (ontologies...)
- entity-scoped query parameters ("individual.age")

- Beacon+ demos "handover" concept

- Beacon hackathon Stockholm; settling on "filters"
- Barcelona goes Zurich developers meeting
- Beacon API v2 Kick off
- adopting "handover" concept
- "Scouts" teams working on different aspects - filters, genomic variants, compliance ...
- discussions w/ clinical stakeholders

- framework + models concept implemented
- range and bracket queries, variant length parameters
- starting of GA4GH review process
- further changes esp. in default model, aligning with Phenopackets and VRS
- unified beacon-v2 code & docs repository
- Beacon v2 approved at Apr GA4GH Connect

Onboarding

Demonstrating Compliance

- Progenetix Beacon+ has served as implementation driver since 2016
- Beacon v2 as service with protocol-driven registries for federation
- GA4GH approved Beacon v2 in April 2022

Beacon v2 GA4GH Approval Registry

Beacons:  European Genome-Phenome Archive |  progenetix |  cnag |  UNIVERSITY OF LEICESTER

 European Genome-Phenome Archive (EGA)

[Visit us](#) [Beacon API](#) [Contact us](#)

GA4GH Approval Beacon Test

This [Beacon](#) is based on the GA4GH Beacon [v2.0](#)

BeaconMap	██████████
Bioinformatics analysis	██████████
Biological Sample	██████████
Cohort	██████████
Configuration	██████████
Dataset	██████████
EntryTypes	██████████
Genomic Variants	██████████
Individual	██████████
Info	██████████
Sequencing run	██████████

 progenetix+

[Visit us](#) [Beacon UI](#) [Beacon API](#) [Contact us](#)

Theoretical Cytogenetics and Oncogenomics group at UZH and SIB

Progenetix Cancer Genomics Beacon+ provides a forward looking implementation of the Beacon v2 API, with focus on structural genome variants and metadata based on the...

BeaconMap	██████████
Bioinformatics analysis	██████████
Biological Sample	██████████
Cohort	██████████
Configuration	██████████
Dataset	██████████
EntryTypes	██████████
Genomic Variants	██████████
Individual	██████████
Info	██████████
Sequencing run	██████████

 Centre Nacional Analisis Genomica (CNAG-CRG)

[Visit us](#) [Beacon API](#) [Contact us](#)

Beacon @ RD-Connect

This [Beacon](#) is based on the GA4GH Beacon [v2.0](#)

BeaconMap	██████████
Bioinformatics analysis	██████████
Biological Sample	██████████
Cohort	██████████
Configuration	██████████
Dataset	██████████
EntryTypes	██████████
Genomic Variants	██████████
Individual	██████████
Info	██████████
Sequencing run	██████████

 University of Leicester

[Beacon UI](#) [Beacon API](#) [Contact us](#)

Cafe Variome Beacon v2

This [Beacon](#) is based on the GA4GH Beacon [v2.0](#)

BeaconMap	██████████
Bioinformatics analysis	██████████
Biological Sample	██████████
Cohort	██████████
Configuration	██████████
Dataset	██████████
EntryTypes	██████████
Genomic Variants	██████████
Individual	██████████
Info	██████████
Sequencing run	██████████

✓ Matches the Spec ✗ Not Match the Spec ● Not implemented


Progenetix Documentation

[Documentation Home](#)[Progenetix Source Code](#)[bycon](#)[progenetix-web](#)[PGX](#)[Additional Projects](#)[News & Changes](#)[Pages & Forms](#)[Services & API](#)[Use Case Examples](#)[Classifications, Ontologies & Standards](#)[Publication Collection](#)[Data Review](#)[Beacon+ & bycon](#)[Technical Notes](#)[Progenetix Data](#)[Baudisgroup @ UZH](#)

Rapidly evolving documentation of both the Beacon API itself and its use and technical implementation on [docs.genomebeacons.org](#) [docs.progenetix.org](#)

- for testing API responses

[/BIOSAMPLES/{ID}/G_VARIANTS](#)

- [/biosamples/pgxbs-kftva5c9/g_variants/](#)
- retrieval of all variants from a single biosample

[Base /individuals](#)[/INDIVIDUALS + QUERY](#)[• /individuals?filters=NCIT:C7541](#)Progenetix Source Code 

With exception of some utility scripts and external dependencies (e.g. [MongoDB](#)) the software (from database interaction to website) behind Progenetix and Beacon+ is implemented in Python.

bycon

- Python based service based on the [GA4GH Beacon protocol](#)
- software powering the Progenetix resource
- [Beacon+](#) implementation(s) use the same code base

progenetix-web

- website for Progenetix and its [Beacon+](#) implementations
- provides Beacon interfaces for the [bycon](#) server, as well as other Progenetix services (e.g. the [publications](#) service)
- implemented as [React / Next.js](#) project
- contains this documentation tree here as [mkdocs](#) project, with files in the [docs](#) directory

Org.progenetix

Search

beacon-v2
☆2 48**Base /biosamples**[/BIOSAMPLES + QUERY](#)

- [/biosamples?filters=cellosaurus:CVCL_0004](#)

• this example retrieves all biosamples having an annotation for the Cellosaurus CVCL_0004 identifier (K562)

[/BIOSAMPLES/{ID}](#)[/BIOSAMPLES/{ID}/TEST_MODE](#)[/BIOSAMPLES/{ID}/TEST_MODE=true](#)[/BIOSAMPLES/{ID}/TEST_MODE=false](#)[/BIOSAMPLES/{ID}/TEST_MODE=false?testMode=true](#)[/BIOSAMPLES/{ID}/TEST_MODE=false?testMode=true&some_random_samples](#)

- for testing API responses

[/BIOSAMPLES/{ID}/G_VARIANTS](#)

- [/biosamples/pgxbs-kftva5c9/g_variants/](#)
- retrieval of all variants from a single biosample

Shoutout to Laure(e)n Fromont & Manuel Rueda for being instrumental in the Beacon v2 documentation!

Beacon API

Beacon-style JSON responses

The Progenetix resource's API utilizes the [bycon](#) framework for data query and delivery and represents a custom implementation of the Beacon v2 API.

The standard format for JSON responses corresponds to a generic Beacon v2 response, with the [meta](#) and [response](#) root elements. Depending on the endpoint, the main data will be a list of objects either inside [response.results](#) or (mostly) in [response.resultSets.results](#). Additionally, most API responses (e.g. for biosamples or variants) provide access to data using [handover](#) objects.

Beacon v2 Documentation

Search

beacon-v2
☆2 48

Org.progenetix

Progenetix & Beacon⁺

The Beacon+ implementation - developed in the Python & MongoDB based [bycon](#) project - implements an expanding set of Beacon v2 paths for the [Progenetix](#) resource [+](#).

Scoped responses from query object

In queries with a complete [beaconRequestBody](#) the type of the delivered data is independent of the path and determined in the [requestedSchemas](#). So far, Beacon+ will compare the first of those to its supported responses and provide the results accordingly; it doesn't matter if the endpoint was [/beacon/biosamples/](#) or [/beacon/variants/](#) etc.

Below is an example for the standard test "small deletion CNVs in the CDKN2A locus, in gliomas" Progenetix test query, here responding with the matched variants. Exchanging the [entityType](#) entry to

- { "entityType": "biosample", "schema": "https://progenetix.org/services/schemas/Biosample/" }

would change this to a biosample response. The example can be tested by POSTing this as [application/json](#) to <http://progenetix.org/beacon/variants/> or <http://progenetix.org/beacon/biosamples/>.


```
{
  "$schema": "beaconRequestBody.json",
  "meta": {
    "apiVersion": "2.0",
    "requestedSchemas": [
      {
        "entityType": "genomicVariant",
        "schema": "https://progenetix.org/services/schemas/genomicVariant"
      }
    ],
    "query": {
      "requestParameters": {
        ...
      }
    }
  }
}
```

Beacon v2 Conformity and Extensions in Progenetix

Putting the **+** into Beacon ...

- support & use of standard Beacon v2 PUT & GET variant queries, filters and meta parameters
 - ➡ variant parameters, genelid, lengths, EFO & VCF CNV types, pagination
 - ➡ widespread, self-scoping filter use for bio-, technical- and id parameters with switch for descending terms use (globally or per term if using POST)
- extensive use of handovers
 - ➡ asynchronous delivery of e.g. variant and sample data, data plots
- **+** extensions of query logic
 - ➡ optional use of OR logic for filter combinations (global)
- **+** extension of query parameters
 - ➡ geographic queries incl. \$geonear and use of GeoJSON in schemas
- ↴ ↵ ↷ ↸ no implementation of authentication on this open dataset


Progenetix provides a number of additional services and output formats which are initiated over the /services path or provided as request parameters and are not considered Beacon extensions (though they follow the syntax where possible).




Progenetix Stack




- JavaScript front-end is populated for query results using asynchronous access to multiple handover objects
 - ▶ biosamples and variants tables, CNV histogram, UCSC .bed loader, .pgxseg variant downloads...
- the complete middleware / CGI stack is provided through the *bycon* package 
 - ▶ schemas, query stack, data transformation (e.g. Phenopackets generation)...
- data collections mostly correspond to the main Beacon default model entities
 - ▶ no separate *runs* collection; integrated w/ analyses
 - ▶ *variants* are stored per observation instance




variants




analyses



biosamples




individuals




- *collations* contain pre-computed data (e.g. CNV frequencies, statistics) and information for all grouping entity instances and correspond to **filter values**
 - ▶ PMID:10027410, NCIT:C3222, pgx:cohort-TCGA, pgx:icdom-94703...
- *querybuffer* stores id values of all entities matched by a query and provides the corresponding access handle for **handover** generation


```
_id: ObjectId("6249bb654f8f8d67eb94953b"),
_id: '0765ee26-5029-4f28-b01d-9759abf5bf14',
source_collection: 'variants',
source_db: 'progenetix',
source_key: '_id',
target_collection: 'variants',
target_count: 667,
target_key: '_id',
target_values: [
  ObjectId("5bab578b727983b2e00ca99e"),
  ObjectId("5bab578d727983b2e00cb505")]
```





collations



geolocs



genespans publications



qBuffer

Entity collections

Utility collections

pgxRpi

An interface API for analyzing Progenetix CNV data in R using the Beacon⁺ API

Beacon Path: Retrieve variants by biosample id(s)

```
https://progenetix.org/beacon/g_variants/
?biosampleIds=pgxb-s-kftvh94d,pgxb-s-kftvh94g,pgxb-s-kftvh972
&output=pgxseg
```

Beacon Path: Get biosamples by filter(s)

```
http://progenetix.org/beacon/biosamples/
?filters=NCIT:C3697&output=datatable
```

Service Path: Retrieve CNV frequencies by filter(s)

```
http://www.progenetix.org/services/intervalFrequencies/
?id=NCIT:C4323&output=pgxseg
```

pgxRpi

This is an API wrapper package to access data from Progenetix database.

You can install this package from GitHub using:

```
install.packages("devtools")
devtools::install_github("progenetix/pgxRpi")
```

If you are interested in accessing CNV variant data, get started from this [vignette](#)

If you are interested in accessing CNV frequency data, get started from this [vignette](#)


When you face problems, try to reinstall the latest version. If reinstallation doesn't help, please contact us.

```
variant_1 <- pgxLoader(type="variant", biosample_id = biosample_id)

biosamples <- pgxLoader(type="biosample", filters = "NCIT:C3059", codematches = TRUE,
                        biosample_id = c("pgxb-s-kftva5zv", "pgxb-s-kftva5zw"))
```

```
freq_pgxseg <- pgxLoader(type="frequency", output = 'pgxseg',
                           filters=c("NCIT:C4038", "pgx:icdom-85003"),
                           codematches = TRUE)
```

```
pgxFreqplot(freq_pgxseg, filters='pgx:icdom-85003')
```



Beacon⁺: Phenopackets

Testing alternative response schemas...

<http://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/phenopackets>

- the v2 default schemas are mostly aligned w/ Phenopackets v2
- creating phenopackets can be done mostly by re-wrapping of Beacon entities (individual, biosample)
- variants can be included through file resource URLs; in Beacon⁺ this is done through *ad hoc* handover URIs

```

    "id": "pgpxpf-kftx3tl5",
    "metaData": {
      "phenopacketSchemaVersion": "v2",
      "resources": [
        {
          "id": "NCIT",
          "iriPrefix": "http://purl.obolibrary.org/obo/NCIT_",
          "name": "NCIt Plus Neoplasm Core",
          "namespacePrefix": "NCIT",
          "url": "http://purl.obolibrary.org/obo/ncit/neoplasm-core.c",
          "version": "2022-04-01"
        },
        {
          "subject": {
            "dataUseConditions": {
              "id": "DUO:0000004",
              "label": "no restriction"
            },
            "diseases": [
              {
                "clinicalTnmFinding": [],
                "diseaseCode": {
                  "id": "NCIT:C3099",
                  "label": "Hepatocellular Carcinoma"
                },
                "onset": {
                  "age": "P48Y9M26D"
                },
                "stage": {
                  "id": "NCIT:C27966",
                  "label": "Stage I"
                }
              }
            ],
            "id": "pgxind-kftx3tl5",
            "sex": {
              "id": "PATO:0020001",
              "label": "male genotypic sex"
            },
            "updated": "2018-12-04 14:53:11.674000",
            "vitalStatus": {
              "status": "UNKNOWN_STATUS"
            }
          }
        }
      ],
      "biosamples": [
        {
          "biosampleStatus": {
            "id": "EFO:0009656",
            "label": "neoplastic sample"
          },
          "dataUseConditions": {
            "id": "DUO:0000004",
            "label": "no restriction"
          },
          "description": "Primary Tumor",
          "externalReferences": [
            {
              "id": "pgx:TCGA-0004d251-3f70-4395-b175-c94c2f5b1b81",
              "label": "TCGA case_id"
            },
            {
              "id": "pgx:TCGA-TCGA-DD-AAVP",
              "label": "TCGA submitter_id"
            },
            {
              "id": "pgx:TCGA-9259e9ee-7279-4b62-8512-509cb705029c",
              "label": "TCGA sample_id"
            },
            {
              "id": "pgx:TCGA-LIHC",
              "label": "TCGA LIHC project"
            }
          ],
          "files": [
            {
              "fileAttributes": {
                "fileFormat": "pgxseg",
                "genomeAssembly": "GRCh38"
              },
              "uri": "https://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/variants/?output=pgxseg"
            }
          ],
          "histologicalDiagnosis": {
            "id": "NCIT:C3099",
            "label": "Hepatocellular Carcinoma"
          },
          "id": "pgxbs-kftvhyvb",
          "individualId": "pgxind-kftx3tl5",
          "pathologicalStage": {
            "id": "NCIT:C27966",
            "label": "Stage I"
          },
          "sampledTissue": {
            "id": "UBERON:0002107",
            "label": "liver"
          },
          "timeOfCollection": {
            "age": "P48Y9M26D"
          }
        }
      ]
    }
  
```

Beacon⁺: Phenopackets

Testing alternative response schemas...

<http://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/phenopackets>

- the v2 default schemas are mostly aligned w/ Phenopackets v2
- creating phenopackets can be done mostly by re-wrapping of Beacon entities (individual, biosample)
- variants can be included through file resource URLs; in Beacon⁺ this is done through *ad hoc* handover URIs

```

{
  "id": "pgxpxf-kftx3tl5",
  "metaData": {
    "phenopacketSchemaVersion": "v2",
    "resources": [
      {
        "id": "NCIT",
        "iriPrefix": "http://purl.obolibrary.org/obo/NCIT_",
        "name": "NCIt Plus Neoplasm Core",
        "namespacePrefix": "NCIT",
        "url": "http://purl.obolibrary.org/obo/ncit/neoplasm-core.owl"
        "version": "2022-04-01"
      }
    ],
    "files": [
      {
        "fileAttributes": {
          "fileFormat": "pgxseg",
          "genomeAssembly": "GRCh38"
        },
        "uri": "https://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/variants/?output=pgxseg"
      }
    ],
    "biosamples": [
      {
        "biosampleStatus": {
          "id": "EFO:0009656",
          "label": "neoplastic sample"
        },
        "dataUseConditions": {
          "id": "DUO:000004",
          "label": "no restriction"
        },
        "description": "Primary Tumor",
        "externalReferences": [
          {
            "uri": "https://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/variants/?output=pgxseg"
          }
        ]
      }
    ],
    "individual": {
      "fileAttributes": {
        "fileFormat": "pgxseg",
        "genomeAssembly": "GRCh38"
      },
      "uri": "https://progenetix.org/beacon/biosamples/pgxbs-kftvhyvb/variants/?output=pgxseg"
    },
    "histologicalDiagnosis": {
      "id": "NCIT:C3099",
      "label": "Hepatocellular Carcinoma"
    },
    "id": "pgxbs-kftvhyvb",
    "individualId": "pgxind-kftx3tl5",
    "pathologicalStage": {
      "id": "NCIT:C27966",
      "label": "Stage I"
    },
    "sex": {
      "id": "PATO:0020001",
      "label": "male genotypic sex"
    },
    "updated": "2018-12-04 14:53:11.674000",
    "vitalStatus": {
      "status": "UNKNOWN_STATUS"
    }
  }
}

```

Beacon⁺: Phenopackets

Testing alternative response schemas...

<http://progenetix.org/beacon/biosamples/pgxbs-kftvhvzb/phenopackets>

- the v2 default schemas are mostly aligned w/ Phenopackets v2
- creating phenopackets can be done mostly by re-wrapping of Beacon entities (individual, biosample)
- variants can be included through file resource URLs; in Beacon⁺ this is done through *ad hoc* handover URIs

```

bios_s = data_db["biosamples"].find({"individual_id":ind["id"]})

for bios in bios_s:

    bios.update({
        "files": [
            {
                "uri": "{}/beacon/biosamples/{}/variants/?output=pgxseg".format(server, bios["id"]),
                "file_attributes": {
                    "genomeAssembly": "GRCh38",
                    "fileFormat": "pgxseg"
                }
            }
        ]
    })
    for k in bios_pop_keys:
        bios.pop(k, None)

    clean_empty_fields(bios)

    pxf_bios.append(bios)

def remap_phenopackets(ds_id, r_s_res, byc):

    if not "phenopacket" in byc["response_entity_id"]:
        return r_s_res

    mongo_client = MongoClient()
    data_db = mongo_client[ds_id]
    pxf_s = []

    for ind_i, ind in enumerate(r_s_res):

        pxf = phenopack_individual(ind, data_db, byc)
        pxf_s.append(pxf)

    return pxf_s

```

The GA4GH Phenopackets v2 Standard

A Computable Representation of Clinical Data




The GA4GH Phenopacket schema consists of several optional elements, each containing information about a certain topic, such as phenotype, variant or pedigree. An element can contain other elements, which allows a hierarchical representation of data.

For instance, Phenopacket contains elements of type *Individual*, *PhenotypicFeature*, *Biosample* and so on. Individual elements can therefore be regarded as **building blocks** of larger structures.

Jacobsen JOB, Baudis M, Baynam GS, Beckmann JS, Beltran S, Buske OJ, Callahan TJ, et al. 2022.

The GA4GH Phenopacket Schema Defines a Computable Representation of Clinical Data.
Nature Biotechnology 40 (6): 817–20.



GA4GH {S}[B]

SchemaBlocks

- “cross-workstreams, cross-drivers” initiative to document GA4GH object standards and prototypes, data formats and semantics
- launched in December 2018
- documentation and implementation examples provided by GA4GH members
- no attempt to develop a rigid, complete data schema
- object vocabulary and semantics for a large range of developments
- currently not “authoritative GA4GH recommendations”
- recognized in GA4GH roadmap as element in "TASC" effort

schemablocks.org

SchemaBlocks

[{S}\[B\] Home](#)
[About SchemaBlocks](#)
[Contacts](#)
[Schemas](#)
[Standards & Practices](#)
[{S}\[B\] Legacy Site ↗](#)
[Beacon Project ↗](#)

{S}[B] Schemas

This page lists (some of the) schemas and schema components from within the GA4GH ecosystem according to their [status levels](#). Emphasis here is to be “instructive” without claims to represent the current or detailed status - please follow the links to the original projects for details.

Status: core

[DUO - DataUseLimitation](#)

The Data Use Limitation is a component of the GA4GH DUO standard and used to describe limitations in the ways data items can be re-used.



[→Continue reading](#)

[DUO - DataUseModifier](#)

The Data Use Modifier is a component of the GA4GH DUO standard and used as optional refinement of the limitations defined in [DataUseLimitation](#).



[→Continue reading](#)

[GA4GH - Checksum](#)

The Checksum standard provides a simple schema for defining a checksum value together with a default type.



[→Continue reading](#)

[Phenopackets - OntologyClass](#)

OntologyClass is an essential core element in GA4GH schemas. It essentially defines the standard way to terms or classes by their `id` - which should be a CURIE - and optionally a `label` for informative purposes.





[→Continue reading](#)

Future?

Some proposals for a stepwise Beacon protocol extension

- Query language expansion, e.g. Boolean options for chaining filters
 - use of heterogeneous/alternative annotations within and across resources
- **Phenopackets** support as a (the?) default format for biodata export
- **Phenopackets** as **request** documents
- Focus on service & **resource discovery**
- **ELIXIR Beacon Network**, including translations for federated queries to Beacon and Beacon-like resources





Have you seen deletions in this region on chromosome 9 in Glioblastomas from a juvenile patient, in a dataset with unrestricted access?



Beacon v2 API

The Beacon API v2 proposal opens the way for the design of a simple but powerful "genomics API".

Progenetix & Beacon⁺

A cancer genomics reference resource powered by GA4GH standards

- Copy number variations constitute a complex, exciting and still poorly understood research topic in cancer and rare disease genomics
- Progenetix is the largest public resource for CNV in cancers (and increasingly reference genomes)
- The complexity of inherited and somatic genomic variations requires data access beyond individual resources => **Federated Data Access**
- The Global Alliance for Genomics and Health (GA4GH) is a policy-framing and technical standards-setting organization with focus on genomic data sharing
- Beacon v2 is the main GA4GH data discovery and sharing protocol, developed with support from the European bioinformatics organization ELIXIR
- Progenetix serves as a testbed for the early implementation of GA4GH standards such as Beacon extensions, Phenopackets and VRS

 GA4GH Genome Beacons 

A Driver Project of the Global Alliance for Genomics and Health GA4GH and supported through ELIXIR

News
Specification & Roadmap
Beacon Networks
Events
Examples, Guides & FAQ
Contributors & Teams
Contacts
Meeting Minutes

Related Sites
ELIXIR BeaconNetwork
Beacon @ ELIXIR
GA4GH
beacon-network.org
Beacon+
GA4GH::SchemaBlocks
GA4GH::Discovery

Github Projects
Beacon API and Tools
SchemaBlocks

Tags
CNV EB FAQ SV VCF beacon clinical
code compliance contacts definitions
developers development events filters
minutes network press proposal
queries releases roadmap
specification teams v2 versions
website

Beacon v2 - Towards Flexibility



Baudisgroup @ UZH
Ni Ai
Michael Baudis
Haoyang Cai
Paula Carrio Cordo
Bo Gao
Qingyao Huang
Saumya Gupta
Nitin Kumar
Sofia Pfund
Rahel Paloots
Ziying Yang
Hangjia Zhao


Pierre-Henri Toussaint

Have you seen deletions in this region on chromosome 9p21 in Glioblastomas from juvenile patient, in a dataset with unrestricted access?


beacon-project.io



{S}[B] and GA4GH
Melanie Courtot
Helen Parkinson
many more ...



beacon.progenetix.org/beaconPlus/



ga4gh-beacon / specification-v2

[Code](#) [Issues 14](#) [Pull requests](#) [Actions](#) [Wiki](#) [Security](#) [Insights](#) [...](#)

About
GA4GH Beacon v2 specification.

ga4gh beacon openapi

Readme
Apache-2.0 License

Releases
No releases published [Create a new release](#)

Packages
No packages published [Publish your first package](#)

Contributors 3
sdelatorrep sdelatorrep
mbaudis mbaudis
blankdots blankdots

ELIXIR h-CNV
Christophe Béroux
David Salgado
many more ...

github.com/ga4gh-beacon/

